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1 Introduction 
“Cancer is the uncontrolled growth of abnormal cells in the body” (A.D.A.M. Medical 
Encyclopedia). In 2010 cancer was one of the major causes of death in the European 
Union (166.9 deaths per 100 000 inhabitants). The history of neoplastic diseases is long: 
a first case of breast cancer was already described in the Edwin Smith Papyrus written 
approximately 3000 BC [1]. 
In the past tumor tissue was seen as an insular mass of proliferating cells, but as cancer 
research progressed in the past years, nowadays neoplastic tissue is understood as a 
complex aggregate of multiple cell types that participate in heterotypic interactions with 
each other. The recent research was compiled in a review of Hanahan and Weinberg in 
2000 [2]. Lately, in a follow up review in 2012 additionally the immune system was 
stressed as a major key player in cancer progression [3]. 
Neoplastic diseases display a remarkable diversity, thus treatment strategies are 
numerous. Besides resection and radiation, chemotherapy plays an important role in 
the treatment of solid tumors. Although potent chemotherapeutics have been 
developed one major hurdle is emerging. In many cases resistance to the applied 
therapy occurs. Two main resistances categories are known: 1) acquired or 2) intrinsic 
chemoresistance. Acquired chemoresistance means that a tumor which has been 
chemosensitive develops resistances against a certain kind of therapy. In contrast, 
intrinsic chemoresistance implies that a neoplastic disease is resistant already before a 
therapy is applied. Fast proliferating malignant cells form the bulk tumor. These cells are 
targeted by chemotherapeutics. However, slow proliferating cells often remain after 
therapy. The diversity of the tumor cells allows the transition of epithelial tumor cells to 
mesenchymal cells (EMT). Mesenchymal cells carry an elevated migratory potential. 
Thus, they are able to evade the tumor and invade other tissues to form metastases. A 
treatment can therefore even facilitate this effect, by killing only a part of the tumor and 
forcing surviving cells to a molecular evolution to increased aggressiveness and 
chemoresistance. 
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1.1 Resistance formation upon metronomic cyclophosphamide therapy 
To overcome acquired resistance to chemotherapeutic treatment is one of the major 
issues of clinical cancer research nowadays. Up to now a variety of molecular 
mechanisms leading to chemoresistance of cancer cells have been investigated and led 
to the development of new treatment strategies. Besides targeted therapy and 
combinatorial treatments, anti-angiogenic therapy is a promising option to circumvent 
resistance formation [4, 5]. For example, in prostate cancer the prognosis for patients 
with hormone resistant prostate carcinoma (HRPC) is poor, because of frequent 
occurrence of chemoresistance often followed by relapse and further tumor progression 
[6, 7]. One suggested follow up therapy for taxane-resistant HRPC is the metronomic 
treatment (frequent administration of low dose) with cyclophosphamide (CPA), 
reviewed by Emmenegger et al., 2010 [8]. 
The alkylating agent CPA, if given in normal dose, preferably targets tumor cells. 
However, metronomic therapy acts as an anti-angiogenic drug [9-11]. 
The pivotal targets of anti-angiogenic therapy are not cancer cells but blood vessels, 
supplying the tumor with nutrients and oxygen. Thus, one advantage of anti-angiogenic 
therapy is that it targets endothelial cells, not carrying a malignant phenotype. These 
cells are, unlike cancer cells, not able to develop resistance to the treatment due to their 
comparably stable genetics. Studying the mechanisms leading to resistance to anti-
angiogenic therapy is of great interest, as they may differ from resistance to classical 
chemotherapy. In general, resistance to anti-angiogenic therapy can be classified into 
four major groups: 1) evasive resistance, 2) vascular cooption, 3) reduced vascular 
dependence and 4) vascular remodeling [12]. 
In 2011 Emmenegger et al. pointed out that the applied CPA dose (maximum dose or a 
metronomic dosing) directly changes the mechanisms of resistance formation. After 
treatment of PC3 xenografts with maximum dose, tumor cells acquired resistance both 
in vivo and in vitro [12]. However after metronomic application of CPA the resistant 
phenotype became manifested only in vivo. Furthermore, Thoenes et al. showed that 
prostate cancer xenografts, treated metronomically with CPA, acquire chemoresistance. 
After a response phase of around 50 days cells develop resistance and tumors size 
increases (Figure 1-1 A). Resistant tumors were reisolated and cell lines were established 
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[13]. An overview of the distinct cell lines is shown in Figure 1-1 C. When analyzed in 
vitro, cells were chemosensitive to the metabolized, active form of CPA (4-HOO-CPA, 
Figure 1-1 B). 
 
 
PC3 wt parental PC3 cell line (ATCC# CRL1435) 
PC3 A3 in vivo passaged control cell line 
PC3 D3 in vivo resistant cell line 
PC3 D4 in vivo resistant cell line 
 
Figure 1-1 Resistance formation upon metronomic cyclophosphamide therapy, from Thoenes et al. [13] 
A. Growth curve of s.c. PC3 wt tumors in SCID mice during metronomic CPA therapy B. in vitro 4-HOO-CPA 
(active form of CPA) treated PC3 clones C. list of cell lines 
As summarized in Figure 1-2 CPA has an anti-angiogenic effect in this model, which is 
still present in the resistant state. Tumor vessels are destroyed and blood supply is 
reduced during the treatment. Tumors developed a resistance to the therapy regimen 
without restoring tumor vessels or vascular mimicry (Figure 1-2 A). Moreover resistant 
cells did neither acquire a multidrug resistance nor detoxified CPA by alcohol 
dehydrogenase ADH or aldehyde dehydrogenase ALDH (Figure 1-2 B, C). Taken together 
the underling mechanism can be proposed as a member of the major group of reduced 
vascular dependence. 
A. B. 
C. 
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Figure 1-2 Overview of potential resistance mechanisms (A. and B. originate from Thoenes et al. [13]) 
 
Isolated tumor cell lines from resistant tumors revealed their resistant phenotype upon 
reimplantation in vivo [13]. A comparative proteome analysis of chemoresistant versus 
parental PC3 cells was performed, suggesting the involvement of Annexin A3 [13]. To 
further analyze the gene expression of chemoresistant tumor tissue in vivo, a genome 
wide microarray of xenografted PC3 tumor cell lines was performed. Four PC3 sublines 
PC3 wt (standard PC3 cells), PC3 A3 (in vivo passaged control cells) and PC3 D3, PC3 D4 
(in vivo resistant cells) were injected subcutaneously into SCID mice (overview of cell 
lines Figure 1-1 C). After tumor formation, one group of each PC3 subline was treated 
with CPA, whereas the other group was kept untreated. Microarray analysis of four 
individual tumors per group was performed. In order to detect distances and similarities 
between different samples, RMA (robust multichip analysis) normalized data were 
subjected to hierarchical clustering. Here a distinct clustering of the different cell lines 
was observed. In contrast, acute CPA treatment of the different tumors did not induce 
additional clusters (Figure 1-3). This indicates only a minor effect of CPA on the gene 
expression profile. The resistant tumor sublines PC3 D3 and PC3 D4 showed a close 
relation of their gene expression profile, suggesting a similar resistance genotype. 
Furthermore, in vivo passaging strongly influenced the gene expression pattern, 
demonstrating the influence of the tumor environment [14]. 
Further analyses were focused on the inherent differences between samples of resistant 
cell lines PC3 D3 and PC3 D4 versus in vivo passaged cell line PC3 A3 without the direct 
influence of CPA. 
A. B. C. 
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Figure 1-3 Robust multichip analysis (RMA) of parental PC3 wt, in vivo passaged PC3 A3, and resistant 
tumors PC3 D3 and PC3 D4  
Hierarchical clustering on robust multichip analysis (RMA) normalized arrays. red = low distance, blue = 
high distance. Outliners, marked by * are excluded from further data analysis. Data originate from PhD 
thesis of Lilja Thoenes (LMU, 2009) and Kubisch et al. [14] 
Analysis of PC3 D3 (resistant) versus PC3 A3 (control) and PC3 D4 (resistant) versus 
PC3 A3 (control) revealed 415 differentially expressed genes for PC3 D3 and 566 for 
PC3 D4. An intersecting set of 212 genes were differentially expressed in both resistant 
tumor lines (Figure 1-4). The expression of dehydrogenase/reductase member 2 
(DHRS2), PAS domain containing protein 1 (PASD1) and special AT-rich sequence-binding 
protein-1 (SATB1) was increased in the resistant tumors compared to PC3 A3 tumors, 
whereas neurotensin (NTS) and bone morphogenetic protein receptor type I B 
(BMPR1B) expression was decreased in resistant tissue (Figure 1-4). 
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Figure 1-4 Microarray analysis (from Kubisch et al. [14]) 
Venn diagram of PC3 D4 versus A3 (566 genes) and PC3 D3 versus PC3-A3 (415 genes) differentially 
expressed genes (+/- 0.4-fold change cutoff) and table including top 10 higher and lower fold expression 
(log2) score of genes differentially expressed by both PC3 D3 and PC3 D4. bold: qPCR validated genes 
An altered exon expression was found for tissue factor (F3). As shown in Figure 1-5 only 
exon 3-6 displays an elevated expression in resistant tumors (PC3 D4). Further analysis 
of the underling mechanisms was to be performed based on these previous findings. 
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Figure 1-5 Microarray expression profile (probe intensity) of F3 (tissue factor) (from Kubisch et al. [14]) 
 
In summary, metronomically administered CPA acts anti-angiogenic by destroying tumor 
vessels. Xenografted PC3 tumors in SCID mice develop a resistance against this therapy 
after around 50 days. Isolated cells do not display a resistant phenotype in vitro but are 
resistant after reimplementation in vivo. Neoangiogenesis, vascular mimicry, enzymatic 
detoxification as well as multidrug resistance (MDR) transporter activity could be ruled 
out as a cause for resistance. Moreover, cells develop a reduced vascular dependence 
leading to resistance to the anti-angiogenic therapy. 
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1.2 Myxobacterial compounds in cancer treatment 
A further approach to overcome resistance or even circumvent resistance formation is 
development of novel anti-cancer drugs. Here, myxobacteria are of great 
pharmaceutical interest as they are producing a variety of secondary metabolites with 
different biological activities. Up to now more than 7,500 myxobacteria have been 
isolated. Many of them were chemically analyzed and about 100 different core 
structures (plus 500 derivatives) are published [15]. The most prominent myxobacterial 
compound, the paclitaxel mimic epothilone is in clinical trials for the treatment of breast 
cancer [16]. Besides tubulin stabilizer epothilone, other myxobacterial compounds like 
the microtubule destabilizer tubulysin and disorazol are known [17, 18]. Furthermore, 
compounds rhizopodin and the chondramides which interfere with the actin filaments 
of eukaryotes are important members of myxobacterial compounds [19-21]. Recently 
three classes of myxobacterial compounds have come into focus: 1) tubulin inhibitor 
tubulysin and its derivatives, 2) the chondramides (F-actin binding) and 3) archazolid A 
and B which are potent V-ATPase inhibitors [22, 23]. A schematic overview of their 
proposed action in the cell is shown in Figure 1-6. 
 
Figure 1-6 Myxobacterial compounds in cancer treatment 
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The tubulysin derivative pretubulysin has been shown to have anti-angiogenic 
properties and thus potently reduced tumor growth of hepatocellular xenografts in vivo 
[24]. Chondramides strongly prevent polymerization of F-actin and thus exhibit a 
cytostatic effect in vitro [21]. Furthermore, both pretubulysin and chondramid B hamper 
lung colonization of 4T1luc breast cancer cells in BALB/c mice (PhD thesis Laura 
Schreiner, LMU 2013). 
1.2.1 Archazolid a novel V-ATPase inhibitor  
Archazolid A and B (Figure 1-7) are macrolactone structures with V-ATPase Inhibitor 
function [22, 23, 25-28]. Both show similar bioactivity [29]. Archazolid induces apoptosis 
in cancer cells in a nanomolar range [30]. Moreover, it was previously shown that it 
inhibits migration of highly metastatic cancer cells in vitro and reduces the lung 
colonization of breast cancer cells in vivo [29]. Notably, other targets are proposed 
despite V-ATPase but not yet proven. 
 
Figure 1-7 Chemical structure of archazolid A and B from Huss et al. [25] 
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1.3 V-ATPase  
The main target of archazolid is the V-ATPase. Vacuolar (H+)-ATPases are found on 
various membranes, including lysosomes, endosomes, vesicles and the plasma 
membrane. As V-ATPases are ATP dependent proton pumps they are crucial for 
maintaining the pH of these compartments. Thus, they play a vital role in various cellular 
processes like, intracellular targeting of lysosomal enzymes, protein processing and 
degradation as well as receptor-mediated endocytosis [31, 32].  
In cancer a combination of increased metabolism and reduced oxygen and nutrient 
supply leads to an acidic tumor environment (reviewed by Vaupel et al. [33]). Thus, 
tumors have to control their intracellular pH strictly. V-ATPases are reported to play a 
crucial role in tumor pH homeostasis of cancer cells either by pumping protons out of 
the cell or into acidic lysosomes [34, 35]. Therefore, compounds inhibiting V-ATPase are 
proposed as novel drugs for cancer therapy (reviewed by Fais et al. [36]).  
V-ATPases are composed of two major domains: 1) peripheral domain V1 and 2) integral 
domain V0. Each domain is composed of different subunits: V1 A-H and V0 a-e (Figure 
1-8). Subunit V1 is responsible for ATP hydrolysis and V0 for proton translocation-
through the membrane. 
Bafilomycin A1 and concanamycin A as well as archazolid are natural compounds 
efficiently inhibiting the V0c subunit of V-ATPases [23, 37-41]. In contrast to archazolid, 
which inhibits V-ATPase function by binding between the membrane and subunit c, 
concanamycin A and bafilomycin A1 are binding between the different subunits c [23]. 
V-ATPase inhibitors display a novel group of anti-cancer compounds, as their unique 
mode of action strongly differs from common anti-cancer drugs. 
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Figure 1-8 Schematic overview of the vacuolar V‑ATPase complex (drawn after Forgac et al. [32]) 
The V-ATPase complex is composed of a peripheral domain (V1), responsible for ATP hydrolysis, and an 
integral domain (V0), involved in proton translocation across the membrane. Here Archazolid binds to the 
proteolipid subunits c and thus blocks H
+
 transfer. 
1.4 Cathepsin B 
In cancer research lysosomal proteases like the cathepsins became more and more 
important as tumor markers. In particular, cathepsin B is upregulated in many types of 
cancer [42-45]. Nevertheless, its distinct role in tumor progression is not fully 
understood and controversially discussed. During metastasis tumor cells are invading 
the surrounding tissue and migrate to distant sites. One of the crucial steps for this 
process is the degradation of extracellular matrix by extracellular proteases (for review 
see [46-48]). Some authors state that extracellular cathepsins directly contribute to 
matrix degradation [49-53]. In contrast, others show that intracellular cathepsin B is in 
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an indirect way crucial for extracellular matrix degradation by other proteases like 
urokinase (uPA) or matrixmetalloproteinases [54, 55]. 
Cathepsin B is synthesized at the rough endoplasmic reticulum (ER) as 
preprocathepsin B (Figure 1-9). Signal peptides target cathepsin B into the ER lumen. 
Here it becomes cleaved co-translationally to procathepsin B. Thereafter, 
procathepsin B is transported through the ER to the Golgi apparatus. Here it is 
substituted with two asparagine-linked mannose-containing oligosaccharides. These 
residues are then phosphorylated. After phosphorylation procathepsin B is bound to 
membrane associated mannose-6-phosphate receptor (M6PR) in the trans-Golgi 
network (TGN). M6PR-procathepsin B containing vesicles are leaving the TGN and direct 
to prelysosomal compartments (PLC). Importantly, the dissociation of the 
M6PR-procathepsin B complex is pH dependent. If the pH in the compartment is 
neutral, the complexes will not dissociate. Consequently, during the lysosome 
maturation process the pH of these PLC is decreasing which leads to the release of 
cathepsin B from the M6PR and recycling of the receptor to the TGN (for review see [56-
58]. 
 
Figure 1-9 Cathepsin B maturation process; a schematic overview 
ER = endoplasmic reticulum, Golgi app. = Golgi apparatus, PLC = prelysosomal compartment, M6PR = 
mannose-6-phosphate receptor  
  
Introduction 
13 
 
1.5 Aim of the thesis 
In this thesis the mechanisms leading to acquired chemoresistance as well as new 
treatment strategies implying the prevention of tumor cell evasion and metastases 
formation will be addressed. 
As chemoresistance is one of the major hurdles in cancer treatment, the elucidation of 
underlying molecular mechanisms is of great interest. Therefore, one aim of this thesis 
is the analysis of the molecular changes after resistance formation upon metronomic 
cyclophosphamide therapy in a prostate cancer model. The analysis is based on a 
microarray gene expression experiment. In particular the clarification of mechanisms 
leading to the survival of tumor cells during maintained, anti-angiogenic, metronomic 
cyclophosphamide therapy is in focus using state of the art bioinformatics and 
expression analysis methods. 
Moreover, new treatment strategies using novel myxobacterial compounds will be 
elucidated, with special regard to the anti-metastatic action of archazolid, a potent 
V-ATPase inhibitor. V-ATPase inhibitors are known to alter endo- and exocytotic events. 
In the current thesis, secreted proteins of archazolid treated, highly migratory urinary 
bladder carcinoma cells should be identified using a proteomic approach. Furthermore, 
the molecular consequences of V-ATPase inhibition on cellular trafficking should be 
elucidated in vitro using different biochemical, molecular biological and imaging 
techniques. Finally, in vitro results should be confirmed in vivo using a syngenic mouse 
model. This model enables the monitoring of archazolid action on cancer cells by the in 
vivo application of mouse mammary gland tumor cells (4T1luc) stably expressing the 
transgene luciferase as a reporter. In the following, the influence of archazolid on tumor 
growth and metastasis then can be analyzed using the in vivo measurement of luciferase 
activity. Moreover, it facilitates to evaluate also other biochemical parameter ex vivo 
after a certain treatment regimen. 
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2 Material and Methods  
2.1 Material  
2.1.1 Cell culture reagents and media 
DMEM 4,5 g/l Glucose Invitrogen (Karlsruhe, Germany) 
RPMI Invitrogen (Karlsruhe, Germany) 
McCoy’s 5A modified medium Biochrom (Berlin, Germany) 
fetal bovine serum (heat inactivated) Invitrogen (Karlsruhe, Germany) 
L-alanyl-L-glutamine  Biochrom (Berlin, Germany) 
trypsin EDTA solution Biochrom (Berlin, Germany) 
Opti-MEM Invitrogen (Karlsruhe, Germany) 
2.1.2 Cells 
PC3 wt (# CRL1435) ATCC, USA 
PC3 A3 [13] 
PC3 D3 [13] 
PC3 D4 [13] 
T-24 Barbara Mayer LMU (Germany) 
4T1luc Caliper (Alamenda, CA, USA) 
MCF-7 Cell line Services (Germany) 
2.1.3 Plastic- and glassware 
well-plates (6,12,24,48 and 98) TPP (Switzerland)) 
tissue culture flask (25,75 and 100 cm
2
) TPP (Switzerland)) 
cell culture dish 10 cm NUNC, USA 
Coverslips and slides  Gerhard Menzel GmbH (Germany) 
Amicon Ultra-4 Centrifugal Filter Units       
(3 and 10 kDa cut off)  
Merck Millipore (USA) 
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2.1.4 Instruments 
Phase contrast microscope Carl Zeiss Axiovert 200 Carl Zeiss (Germany) 
Fluorescence microscope Carl Zeiss Axiovert 200 Carl Zeiss (Germany) 
Laser scanning microscope Carl Zeiss Laser Scanning 
Microscope LSM 510 Meta 
Carl Zeiss (Germany) 
CyAnTM ADP Dako cytomations (Germany) 
LightCycler 480 system Roche (Germany) 
Luminometer Lumat LB9507 instrument Berthold (Germany) 
FastPrep-24 tissue/ cell homogenizer MP Biomedicals GmbH (Germany) 
Hybaid PCR thermal cycler  Thermo Fisher Scientific (USA) 
Tecan spectra fluor plate reader Tecan (Switzerland) 
SDS-Page Running system Biorad (Germany) 
Wet-Blot-System Biorad (Germany) 
Olympus BX41 microscope 
 
Olympus (Japan) 
2.1.5 Kits 
CellTiterGlo  Promega (USA) 
Transcriptor High Fidelity cDNA Synthesis  Roche (Germany) 
NucleoSpin RNA II  Macherey and Nagel (Germany) 
BCA-Assay  Thermo Fisher Scientific (USA) 
iTRAQ® Reagent 4plex AB Sciex (USA) 
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2.1.6 Antibodies 
antigen  art.-no. source company WB IF 
alpha-Tubulin T9026 mouse  sigma-aldrich (USA) 1:10,000 
 ANXA3 PA5-12438 rabbit Thermo Scientific (USA) 1:1000 1:200 
Cathepsin B  IM27L mouse Calbiochem (Germany) 1:500 1:200 
Cathepsin B  #3383 rabbit CST (USA) 1:1000 
 
Cathepsin D #2284 rabbit CST (USA) 1:1000 
 
F3 sc-23596 goat SantaCruzBiotech. (USA) 1:1000 
 
GAPDH #2118 rabbit CST (USA) 1:5000 
 
M6PR (IGF-IIR) sc-25462 rabbit SantaCruzBiotech. (USA) 
 
1:50 
SATB1 ab49061 rabbit Abcam (USA) 1:1000 1:200 
2.1.7 Primer 
Primer human  
ATP6V0C  UPL Probe #76 left: ttcgtttttcgccgtcat,  
right ccactgggatgatggacttc 
ACTIN BETA  UPL Probe #64 left: ccaaccgcgagaagatga,  
right ccagaggcgtacagggatag 
ANXA3  UPL Probe #29 left: tccggaaagctctgttgact, 
right: atcttgtttggccagatgct 
B2M  UPL Probe #42 left: ttctggcctggaggctatc,  
right: tcaggaaatttgactttccattc 
BMPR1B  UPL Probe #21 left: tttcatgccttgttgataaaggt, 
right: gcttgtttaactttttgtttcctctc 
CATHEPSIN B UPL Probe #26 left: ttcggacttcctgctctacaa 
right: tagggtgtgccattctccac 
CATHEPSIN D UPL Probe #37 left: ggtacctgagccaggacact 
right: acctgcctctccactttgac 
DHRS2  UPL Probe #4 left: tgagactatcacctatcgccaag, 
right: cagcatagtggttggtgtctg 
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F3 Exon 1-2  UPL Probe #15 left: cgccaactggtagacatgg, 
right: gctgccacagtatttgtagtgc 
F3 Exon 5-6  UPL Probe #2 left: cagacagcccggtagagtgt, 
right: ccacagctccaatgatgtagaa 
GAPDH UPL Probe #60 left: ctctgctcctcctgttcgac,  
right: gcccaatacgaccaaatcc 
NTS  UPL Probe #17 left: cagcttgtatgcatgctactcc, 
right: aatgctttcatttcctcttctga 
PASD1  UPL Probe #20 left: caacccacctaccatcaggt, 
right: ctgctccgcagat ctcatc 
PLAT  UPL Probe #59 left: cgggtggaatattgctggt,  
right: cttggctcgctgcaactt 
PROS1  UPL Probe #46 left: acatacctgggtggccttc,  
right: tccagatccaactgtacaccat 
SATB1  UPL Probe #44 left: aatggcattgctgtctctagg, 
right: actttccaacctggattagcc 
SERPINA1  UPL Probe #73 left: gcttaaatacggacgaggaca, 
right: acgagacagaagacggcatt  
SERPIND1  UPL Probe #29 left: tggtggagagatggcaaaa, 
right:gattgtagttcttctccagcttgaat 
SERPINB7  UPL Probe #8 left: gattgtagttcttctccagcttgaat, 
right: caaattgaacttccgttcctg 
Primer mouse 
ACTIN BETA  UPL mouse ACTB Gene Assay, Roche (Germany) 
CATHEPSIN B UPL Probe #47 left: gtgtctgctgaagacctgctt 
right: gggatagccaccattacagc 
CATHEPSIN D UPL Probe #79 left: gcgtcttgctgctcattct  
right: acttgcgcagagggattct 
GAPDH UPL mouse GAPDH Gene Assay, Roche (Germany) 
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2.1.8 Chemicals and Solutions 
Hoechst 33342  Sigma Aldrich (Germany) 
Paraformaldehyde Sigma Aldrich (Germany) 
Triton X 100 Sigma Aldrich (Germany) 
Gelatin solution Sigma Aldrich (Germany) 
FlourSave mounting reagent Merck KGaA (Germany) 
Bafilomycin A1 Sigma Aldrich (Germany) 
Concanamycin A Sigma Aldrich (Germany) 
Tunicamycin Sigma Aldrich (Germany) 
Brefeldin Sigma Aldrich (Germany) 
Cyclophosphamide Sigma Aldrich (Germany) 
Complete®  Roche (Germany) 
Cell lysis buffer Promega (USA) 
Lumi-Light Western Blotting Substrate Roche (Germany) 
X-ray films Fisher Scientific 
DAPI Sigma Aldrich (Germany) 
CA-074 ME (cathepsin B inhibitor) Enzo Life Sciences (USA) 
Z-Arg-Arg-7-amino-4-methylcoumarin 
hydochlorid (cathepsin B substrate) 
 
Sigma Aldrich (Germany) 
Archazolid A was purified and isolated as described previously [22], archazolid B was 
chemically synthesized by Roethle et al. [28]. Both compounds were dissolved in dimethyl 
sulfoxide (DMSO) and show similar bioactivity (supplementary information of Wiedmann 
et al. [29]). For all in vitro experiments archazolid B was used. For all in vivo experiments 
archazolid A was used. 
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2.2 Methods 
2.2.1 Cathepsin B activity assay 
Cathepsin B activity assay was performed in a modified version of the protocol published by 
Barrett, 1980 [59]. The assay buffer was titrated from 2 buffers to get a distinct pH: buffer 1: 
0.1 M NaH2PO4, 0.4 M NaCl, 10 mM EDTA and buffer 2: 0.1 M Na2HPO4, 0.4 M NaCl, 10 mM 
EDTA. In a first experiment different pH values were tested (Figure 2-1). All other 
experiments were carried out using an assay buffer of pH 6.5. pH 6.5 was the pH were the 
cathepsin B activity was in a medium range. By choosing this pH is should be avoided to 
activate procathepsin B by mature cathepsin B. Assay procedure was carried out as follows: 
First assay buffer was placed into a reaction tube. 2 mM cysteine and 30 µg total protein 
sample was added. For background subtraction in one of two samples a specific cathepsin B 
inhibitor (CA-074 ME, 50 µM) was added. To start the reaction 50 µM Z-Arg-Arg-7-amino-4-
methylcoumarin hydrochloride a fluorogenic cathepsin B substrate was supplemented. After 
an incubation time of 30 min at 40 °C the reaction was stopped by adding 2 M Tris (pH is 
raised to 10). Fluorescence of the cleaved substrate was quantified using a tecan reader 
(em 360 nm, ex 450 nm). To determine the specific cathepsin B activity values were 
calculated blank (without sample) and inhibitor corrected. 
 
Figure 2-1 pH dependent cathepsin B activity of recombinant cathepsin B  
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2.2.2 Cell culture  
PC3 human prostate carcinoma cells (PC3 wt, ATCC # CRL1435) and reisolated clones PC3 A3, 
PC3 D3 and PC3 D4 as well as 4T1luc breast cancer cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS. T-24 cells were cultured in McCoy´s modified 5A media 
supplemented with 10% FBS. Cells were grown at 37°C in 5% CO2 in a humidified 
atmosphere. Generation of PC3 subclones was previously described by Thoenes et al. [13]. 
Briefly standard PC3 cells (PC3 wt) had been injected into male SCID mice and treated with a 
metronomic regimen of CPA (120 mg/kg every 6 days). After a response phase, tumors 
restarted growing. Cells of two different resistant tumors were isolated (PC3 D3 and PC3 D4). 
Additionally, a cell lines of untreated tumors was established (PC3 A3), representing an 
in vivo passaged control cell line ([13] and Figure 1-1 C). 
2.2.1.2 Freezing and thawing of cells  
For cell storage in liquid nitrogen, freezing medium (90% culture medium and 10% DMSO) 
was added to the cell pellet. For a slowly freezing of the cells, vials were put into an 
isopropanol containing container and stored at -80°C for at least 24 hours. Thereafter vials 
were transferred into liquid nitrogen. For reculturing of the cells, the cell suspension was 
thawed at 37°C. To remove DMSO residues a media change was carried out 24 hours later. 
2.2.3  Isolation of primary human monocytes 
All experiments including human primary monocytes and macrophages were done in 
cooperation with Professor Dr. Oliver Werz, Chair of Pharmaceutical / Medicinal Chemistry, 
University of Jena. For isolation of PBMC (peripheral blood mononuclear cells) human buffy 
coats (fraction of an anti-coagulated blood sample containing blood cells and platelets 
following density gradient centrifugation) were diluted 1:1 with PBS. To remove erythrocytes 
1:5 dextran was added and samples were incubated for 30-45 min at RT until dextran bound 
erythrocytes were sedimented. Supernatants were collected and slowly put onto density 
gradient centrifugation media (LSM 1077 lymphocyte separation media (PAA, GE Healthcare, 
UK).  
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Figure 2-2 Schematic overview of the different phases after density gradient centrifugation 
 
After centrifugation at 2000 rpm for 10 min (without break) PBMC can be found in the in a 
grey phase indicated in Figure 2-2. PBMC fraction was washed two times with ice cold PBS 
(1200 rpm, 4 °C) counted and 400 x 10
6
 vital cells were seeded per 100 cm
2 
flask in 10% FCS 
containing RPMI media. After 1 - 1.5 hours floating cells were removed. After two washing 
steps with PBS cells were detached by using a cell scraper. For the secretome analysis 5 x 10
6
 
vital cells were seeded per 25 cm
2
 flask in 10% FCS RPMI. After 1 hour monocytes were 
attached and treatment was performed after two washing steps in FCS free RPMI media. 
For macrophage differentiation 15 x 10
6
 vital monocytes were seeded per 100 cm
2
 flask in 
5% FCS containing RPMI + 25 ng/ml hM-CSF (human macrophage-colony stimulating factor). 
Differentiation was carried out for 6 days. Subsequently, 5 x 10
6
 vital macrophages were 
seeded per 25 cm
2
 flask. After 1 hour cells were attached and treatment was performed in 
FCS free RPMI media after 2 washing steps. 
2.2.4 Cell viability assay (CellTiterGlo) 
To analyze the cell viability the CellTiterGlo assay was applied. This assay detects the ATP 
content of a given sample, thus indicating the relative amount of metabolizing, living cells in 
an ATP dependent luciferase reaction. 
CellTiterGlo assay was performed according to the manufacturer’s instructions. Shortly cells 
were seeded in 96-well plates. 24 hours after seeding cells were treated with the respective 
compound in FCS free media. After compound incubation half of the volume of each well 
was replaced by the reaction buffer containing cell lysis buffer, ATP depended luciferase and 
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a luciferase substrate. The luminescence was recorded using a Luminometer Lumat LB9507 
instrument. 
2.2.5 Data-analysis (Microarray) 
Functional analysis of regulated genes was performed using DAVID bioinformatics [60]. 
Description by [60] specifies the stated p-value as the threshold of EASE Score, a modified 
Fisher Exact P-Value, for gene-enrichment analysis. It ranges from 0 to 1. Fisher Exact P-value 
= 0 represents perfect enrichment. Usually P-values equal or smaller than 0.05 are 
considered strongly enriched in the annotation categories. 
2.2.6 In vivo experiments 
Mice were housed in individually ventilated cages, under specific pathogen free conditions, 
with a 12 hours day/night cycle and food and water ad libitum. All animal procedures were 
approved and controlled by the local ethics committee and carried out according to the 
guidelines of the German law of protection of animal life 
2.2.6.1 Warfarin and CPA combinatorial therapy of PC3 A3 tumors 
For tumor formation 1 x 10
6
 PC3 A3 cells in 100 µl PBS were injected subcutaneously with a 
25 G needle into the flank of SCID mice (CB17/lcr-PrkdcSCID/Crl) (8–10 weeks) with 5-7 
animals per group. Two of in total four groups were treated with CPA (120 mg/kg every 6. 
day, i.p.) starting at day 12 after tumor inoculation. The other two groups served as control. 
One of the CPA groups and one of the control groups were treated additionally with 
warfarin, starting at day 11 after tumor inoculation. Until day 18, warfarin was administered 
over the drinking water (7.5 mg/l).  
Warfarin was solved in ethanol. Accordingly the water of the control groups was 
supplemented with the corresponding amount of ethanol (max. 750 µl in 1 l). Although 
acceptance of the ethanol and warfarin supplemented drinking water was tested in a pretrial 
(data not shown), mice stopped drinking around day 16. The treatment regimen was 
changed to warfarin 5 mg/kg i.p. every third day. Mice of the non CPA treated groups were 
euthanized, if the tumor volume was higher than 1000 mm³. On day 57 the experiment had 
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to be stopped due to severe weight loss. For analysis mice of the CPA treatment groups 
which had to be euthanized before day 57 were excluded. 
2.2.6.2 4T1luc tumors 
In a first experiment 2 x 10
6
 4T1luc cells were injected into the flanks of BALB/c mice. At 
day  3, mice were treated 3 times per week i.v. with 3 mg/kg archazolid (n=7), 0.1 mg/kg 
pretubulysin (n=8), 0.5 mg/kg chondramid B (n=8) or vehicle control (5% DMSO in PBS). 
Tumors were measured every two to three days with a caliper, using the formula a x b2/2 (a 
as the largest side of the tumor and b the largest side vertical to a). On day 18 mice were 
euthanized. During the experiment 3 archazolid treated mice had to be euthanized due to 
tail inflammation caused by subcutaneous archazolid. In the following special effort was 
applied to directly inject i.v.. Analysis was done with archazolid n=4.  
In a second experiment 2 x 10
6
 4T1luc cells were injected subcutaneously into the flank of 
BALB/c mice (10 per group). One group was treated with 3 mg/kg archazolid A in 5% 
DMSO/PBS or equal amounts of 5% DMSO/PBS in a second control group. Treatment was 
performed on day 2, 3, 4, 5, 6, 9, 13 and 17 after tumor inoculation. The average tumor 
volumes of the two groups were compared over time. On day 18, mice were sacrificed 
through cervical dislocation. Tumor, lung, liver, kidney and heart of each animal were 
harvested. 
2.2.7 Ex vivo luciferase imaging 
To detect distant metastases of 4T1luc cells in the lung, whole lungs were homogenized 
using a FastPrep-24 tissue/cell homogenizer MP. After homogenization samples were 
centrifuged 13,000 rpm for 10 min at 4°C. Luciferase activity of each sample was determined 
using a Luminometer Lumat LB9507 instrument. 
2.2.8 H&E staining 
Tumors were fixed in formalin and embedded into paraffin. Subsequently paraffin embedded 
tumors were cut with a microtome into 4.5 μm slices and stained with hematoxylin (2 min) and 
eosin (5 min). Results were documented, using an Olympus BX41 microscope. 
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2.2.9 Proteomics 
2.2.9.1 In-gel-digestion 
After electrophoresis, gels were scanned and each lane was cut into similar pieces. Each 
piece was transferred into a reaction tube and covered with 45 mM DTT in 50 mM NH4HCO3. 
After an incubation of 30 min at 55 °C gel-pieces were covered with 100 mM iodoacetamide 
in 50 mM NH4HCO3 for 15 min at RT in the dark. This step was repeated. Subsequently, gel-
pieces were washed two time using 50 mM NH4HCO3. For tryptic digestion pieces were 
chopped using a pipet tip and covered with 50 mM NH4HCO3 containing trypsin in a ratio of 
1 µg trypsin to 50 µg of protein. Incubation was carried out at 37 °C overnight. After the 
digestion supernatants were collected and pieces covered with 70 % acetonitrile for 10 min. 
Supernatants were combined afterwards. After freeze-drying peptide samples were stored 
at -80 °C until LC-MS/MS measurement.  
2.2.9.2 LC-MS/MS analysis 
All LC-MS/MS measurements were done in cooperation with Dr. Thomas Froehlich and 
Dr. Georg J. Arnold (Genzentrum, LMU, Munich, Germany). 
Nano-LC separation was done with a nano-liquid chromatography system (Ettan MDLC, GE 
Healthcare, USA). Peptide samples were loaded on a trap column (10 µl per min, loading 
buffer: 0.1% formic acid; trap column: C18 PepMap 100, 5 µm bead size, 300 µm i.d., 5 mm 
length, LC Packings, USA) and separated with an analytical reversed phase column (Reprosil-
Pur C18 AQ, 3 µm; 150 mm x 75 µm, Dr. Maisch, Germany) using a 30 min gradient from 0 % 
B to 60% B (solvent A: 0.1 % formic acid; solvent B: 84% CH3CN/0.1 % formic acid), at a flow 
rate of 280 nl/min. For electrospray ionization a distal coated SilicaTips (FS-360-20-10-D-20, 
New Objective, USA) and a needle voltage of 1.7 kV was used. Tandem mass spectrometry 
was performed with an Orbitrap XL mass spectrometer (Thermo Scientific, USA). MS and 
MS/MS spectra were acquired using cycles of one MS scan (mass range m/z 300-2000) and 
five subsequent data dependent CID MS/MS scans (“dynamic exclusionTM activated”; 
collision energy: 35%). RAW data were processed using MASCOT Daemon and MASCOT 
Server (V2.3, Matrix Science, Boston, USA) with the human subset of the SwissProt Database 
(Release 2012_11) and the following parameters: a) “Fixed modifications”: Carbamidomethyl 
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(C) b) Variable modifications: Oxidation (M); c) Decoy database: checked, d) Peptide charge: 
1+, 2+ and 3+; e) Peptide tol. ±: 2 Da; f) MS/MS tol. ±: 0.8 Da.  
To generate a high quality dataset of secreted proteins and in order to minimize the number 
of false positive identifications the results were evaluated with the Scaffold software using 
the Peptide Prophet and Protein Prophet algorithms [61]. The probability threshold for 
identified proteins was set to ≥ 99% and exclusively IDs with at least 2 individual peptides 
were accepted. The reliability of the data was further evaluated by counting false positive 
MASCOT hits from the Decoy database [62]. 
2.2.10 Gene expression profiling 
2.2.10.1 RNA isolation 
Cell culture samples were lysed after treatment using cell lysis buffer of the nucleo spin RNA 
Isolation Kit (Macherey-Nagel). For isolation of RNA from tumor samples 30 mg of each 
tumor was lysed in 350 µl of cell lysis buffer additionally using FastPrep-24 tissue / cell 
homogenizer for tissue disruption. RNA isolation was performed according to the 
manufacturer’s instructions.  
2.2.10.2 Reverse transcription 
1 µg of isolated RNA was transcribed with the Transcriptor High Fidelity cDNA Synthesis Kit 
(Roche) according to manufacturer’s protocols using oligo-dT-primer. 
2.2.10.3 Quantitative real-time PCR (qPCR) 
Quantitative real-time PCR was performed using UPL Probes (Roche) and Probes Master 
(Roche) on a LightCycler 480 system (Roche) using GAPDH, Actin B and B2M as controls. 
Experiments were done in triplicates and the obtained average CT values of target genes 
were normalized to control as ΔCT. Changes in expression levels were shown as fold 
expression (2
-ΔΔ CT
), calculated by the ΔΔCT method [62]. 
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2.2.11 Protein analysis 
2.2.11.1 Collection of cell culture supernatants 
1 x 10
6
 T-24 or MCF-7 cells were seeded per 10 cm dish or 1.5 x 10
6
 cells per 75 cm² flask. 24 
hours after seeding cells were washed 3 times (for proteomic analysis) or 1 time (western 
blot) with FCS free media. After treatment of the cells in 10 ml of FCS free media, 
supernatants were harvested, followed by centrifugation of 5 min at 1000 rpm to remove 
cells and cell debris. Supernatants were concentrated to a total volume of 50 µl using 
Amicon Ultra-4 Centrifugal Filter Units (cut off 3 kDa for proteomics and 10 kDa for western 
blot). 
2.2.12 Preparation of whole cell lysates 
After treatment cells were washed with cold PBS and lysed using 0.5 x cell lysis buffer from 
Promega. Cells were lysed on ice for 10 min and centrifuged at 13,000 rpm for 20 min to 
remove cell debris.  
2.2.12.1 Protein quantification 
Protein concentration was determined using the BCA (bicinchoninic acid) Protein Assay Kit 
from Thermo Scientific. The assay principle is that distinct protein side chains are reducing in 
an alkaline medium Cu
2+
 to Cu
1+.
 Bicinchoninic acid selectively detects generated Cu
1+
 by a 
colorimetric reaction. BCA assay was performed in 96-well format according to the 
manufacturer’s instructions. Shortly, 5 µl of sample or standard solution were incubated 
with 200 µl of reaction reagent for 30 min at 36 °C. Absorption was quantified at 590 nm with 
background correction at 630 nm using a tecan plate reader.  
2.2.12.2 SDS-PAGE 
The SDS-PAGE was performed according to Laemmli et al. [63]. 15-50 µg of total protein 
lysate or 30 µl concentrated supernatant were supplemented with Laemmli buffer and 
boiled for 5 min at 95 °C for protein denaturation. Samples were loaded on 10% or 12.5% 
SDS-PA-gels. Protein separation was performed at 0.03 mA per gel for approximately two 
hours. 
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2.2.12.3 Western Blot 
After separation proteins were transferred to a nitrocellulose membrane by wet-blotting 
using the Mini Trans-Blot system from Biorad, Germany.  
For each gel a sandwich was prepared where the gel and a nitrocellulose membrane are 
enclosed by two filter papers. The sandwiches were placed in the apparatus with the gel 
facing the cathode and the membrane facing the anode, to allow the negatively charged 
proteins (negative charge of associated SDS) to migrate from the gel onto the membrane. 
Blotting was performed in transfer buffer at 100 V for 35 min.  
After blotting membranes were incubated with NET-gelatin buffer to block free protein 
binding sides of the membrane for 45 min. Incubation of the primary antibody was 
performed in NET-gelatin buffer at 4 °C overnight. Subsequently, primary antibody was 
removed and membranes were washed three times for 10 min with NET-gelatin buffer. 
Incubation of secondary antibodies coupled to peroxidase was done for 1 hour at room 
temperature, followed by a second washing step (3 x 10 min). 
For developing the specific protein signals membranes were incubated with peroxidase 
substrate (Lumi-Light Western Blotting Substrate, Roche) for 5 min and chemiluminescence 
was detected by exposing the membranes to X-ray films for a distinct time period. 
2.2.13 siRNA transfection 
Cells were seeded in 10 cm dishes or 6-well plates. 24 hours after seeding and at a 
confluence of approximately 70% cells were transfected using lipofectamine 2000 reagent 
from Invitrogen. If put together Lipofectamine 2000 reagent forms liposomes with siRNA 
leading to an enhanced uptake into the cell. Lipoplexes were formed prior to transfection by 
adding siRNA in Opti-MEM to Lipofectamine 2000 in Opti-MEM. In a 10 cm dish 600 pmol 
siRNA (control or target siRNA) in 1.5 ml Opti-MEM and 60 µl Lipofectamine 2000 in 1.5 ml 
were used and were later added to 10 ml of cell culture media. In a 6-well 100 pmol siRNA 
(control or target siRNA) in 250 µl Opti-MEM and 10 µl Lipofectamine 2000 in 250 µl Opti-
MEM were used and were later added to 2 ml of cell culture media. Lipoplexes were formed 
for 20 min at RT ad subsequently added to the cells. 4 hours later to transfection media was 
changed. Analysis was performed 24 and 48 hours post transfection. Control siRNA sequence: 
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5’-AUGUAUUGGCCUGUAUUAG-3’ (sense) V-ATPase subunit V0c: SMARTpool: ON-TARGETplus 
ATP6V0C siRNA, Thermo Fisher Scientific (USA). 
2.2.14 Lysotracker staining 
Cells were seeded in chamber slides. 24 hours after seeding archazolid treatment was 
performed. For lysosome staining 75 nM LysoTracker (Invitrogen) was added to the culture 
medium and incubated for 30 minutes. To stain the nuclei, Hoechst was added in a final 
concentration of 1 μg/ml and incubated for 5 minutes. 
2.2.15 Confocal microscopy 
2 x 10
4
 cells were seeded on coverslips in 6-well plates. After treatment they were fixed with 
4% PFA for 15 min. For intracellular staining samples were permeabilized with 0.2% 
triton X 100 in PBS for 10 min followed by blocking with 10% FCS + 0.05% Triton X 100 in PBS 
for 45 minutes. Incubation with indicated primary antibodies (1:100-1:200) was performed 
for one hour at RT or overnight at 4 °C, followed by incubation with respective secondary 
antibodies (1:400) for 1 hour and Hoechst or DAPI (1 µg/ml) for 10-15 min. Coverslips were 
mounted using FlourSave (Calbiochem) mounting medium. Images were captured using 63 X 
1.4 Oil DIC objective of Laser Scanning Microscope LSM 510 Meta and analyzed using Zeiss 
image browser version 3.2.0.115. 
2.2.16 Statistical analysis 
For statistical significance unpaired Students t-test was performed using GraphPadPrismTM. 
P-values < 0.05 were considered as significant. Furthermore in the ex vivo luciferase 
experiment significant outlier were removed using Grubbs' test (alpha = 0.05). 
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3 Results  
3.1 Gene expression analysis of resistance formation upon metronomic CPA 
therapy  
To analyze the changes in gene expression after resistance formation upon metronomic 
cyclophosphamide therapy a microarray was performed previously as described in the 
dissertation of Lilja Thoenes (2009, LMU) and in the introduction part (1.1).  
In the following the validation and a detailed evaluation of the microarray results is 
presented. Analysis was focused on the differences between tumors of the in vivo passaged 
control cell line PC3 A3 and tumors of the two resistant cell lines PC3 D3 and PC3 D4. The 
most differentially regulated genes dehydrogenase/reductase member 2 (DHRS2), PAS 
domain containing protein 1 (PASD1) and neurotensin (NTS) as well as resistance related 
genes special AT-rich sequence-binding protein-1 (SATB1) and morphogenetic protein 
receptor type I B (BMPR1B) were chosen for microarray validation. Moreover, the 
involvement of two distinct genes 1) SATB1 and 2) ANXA3 was further evaluated. 
Furthermore, a KEGG-Pathway analysis revealed 3 potentially resistance associated 
pathways. 
3.1.1 Validation of regulated genes 
To validate the microarray results (Figure 1-4) five genes were chosen for qPCR analysis. 
Confirming the microarray results, expression of DHRS2, PASD1 and SATB1 was increased in 
resistant tumors compared to PC3 A3 control tumors. NTS and BMPR1B expression was 
decreased in resistant tissue (Figure 3-1).  
In general, gene regulations were stronger in PC3 D4 than in PC3 D3. For example DHRS2 
expression was increased 11-fold in PC3 D4 and 7-fold in PC3 D3. BMPR1B was reduced 
significantly in PC3 D4, whereas in PC3 D3 BMPR1B was only marginally reduced. 
Furthermore, expression of PASD1 was induced 11.7-fold in PC3 D3 and 9.1-fold in PC3 D4 
compared to PC3 A3 control tumors. Also SATB1 expression was induced in resistant tissue 
(2.4-fold in PC3 D3 and 2.3-fold in PC3 D4). In contrast, expression of NTS was clearly 
reduced in resistant sublines (5-fold in PC3 D3 and PC3 D4) (Figure 3-1).  
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Figure 3-1 Target gene expression 
Validation of differentially expressed genes by qPCR: A. dehydrogenase/reductase member 2 (DHRS2), PAS 
domain containing protein 1 (PASD1), special AT-rich sequence-binding protein-1 (SATB1), B. neurotensin (NTS) 
and bone morphogenetic protein receptor, type I B (BMPR1B) *p < 0.05, **p< 0.005, ***p<0.0005 (t-test) 
As resistant cell lines displayed their resistance only upon reimplantation in vivo and were 
sensitive to the activated form of CPA (4-HOO-CPA) in vitro (Figure 1-1 B), the expression of 
these five genes in the sublines under cell culture conditions was analyzed. As shown in 
Figure 3-2, in vitro expression of these genes clearly differed from in vivo expression. 
Whereas, DHRS1, PASD1 and SATB1 were less but still differentially expressed in resistant 
cell lines PC3 D3 and PCR D4, NTS and BMPR1B were not significantly reduced in vitro. 
 
Figure 3-2 Target gene expression in vitro 
Target gene expression in cell culture was analyzed by qPCR: A. dehydrogenase/reductase member 2 (DHRS2), 
PAS domain containing protein 1 (PASD1), special AT-rich sequence-binding protein-1 (SATB1), B. neurotensin 
(NTS) and bone morphogenetic protein receptor, type I B (BMPR1B) *p < 0.05, **p< 0.005, ***p<0.0005 (t-test) 
 
3.1.2 Generation and analysis of ANXA3 and SATB1 over expressing PC3 clones 
As the microarray results were approved by qPCR, the particular involvement in 
chemoresistance of two distinct genes was checked. 1) SATB1, a transcription factor, which 
A. B. 
A. B. 
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was reported to play a role in resistance upon cisplatin resistance in hepatocellular 
carcinoma [64] and 2) ANXA3, a protein previously found in a proteomic study to be more 
abundant in resistant PC3 clones on protein level [13]. In cooperation with Mark Laible, 
Stephanie Blaich and Melanie Hudler (DKFZ, Heidelberg) PC3 clones were stably transfected 
with SATB1 (PC3 SATB1), ANXA3 (PC3 ANXA3) or an empty vector construct (PC3 ev). The 
target genes are expressed under the regulation of a doxycycline dependent promoter. To 
ensure a stable over-expression a system which uses homologous recombination was 
applied (see dissertation of Stephanie Blaich, Ruprecht - Karls – Universität Heidelberg, 2007 
for details). To control the correct expression of the target genes mRNA and protein 
expression was determined by qPCR and western blot analysis. PC3 SATB1 and PC3 ev 
(control) were seeded. 24 hours later the expression was induced with 50 nM doxycycline 
for another 24 hours. Induction of the target gene expression was analyzed by qPCR. Results 
are shown in Figure 3-3 A. SATB1 expression was strongly induced by doxycycline in 
PC3 SATB1 but not in the empty vector control. Notably, PC3 SATB1 already expressed minor 
amounts of SATB1 mRNA without induction of doxycycline. In a next step the correct 
translation of the protein was analyzed by western blot. As shown in Figure 3-3 B detectable 
amounts of SATB1 were only expressed by induced PC3 SATB1 cells. 
 
 
Figure 3-3 Validation of PC3-SATB1 by qPCR and western blot 
A. qPCR of RNA B. western blot of protein lysates isolated from induced (24 hours, 50 nM doxycycline (+dox)) 
and not induced (-dox) PC3 SATB1 cells and PC3 ev (control). 
To evaluate the correct localization of SATB1 inside the cell, immuno-fluorescence imaging 
was performed. As shown in Figure 3-4 SATB1 protein was localized in the nucleus of 
doxycycline induced PC3 SATB1 cells. 
A. B. 
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Figure 3-4 Immuno-fluorescence imaging of PC3-SATB1 
PC3-SATB1 cells were cultivated on coverslips in 6-well plates and A. not induced (control) or B. induced using 
50 nM doxycycline for 24 hours; blue = nuclei (Hoechst) green = SATB1 (alexa 488) 
Subsequent to validation of the correct inducible over-expression of SATB1 in PC3 SATB1 
cells its influence on the chemo-sensitivity in vitro was evaluated. CPA is a prodrug which is 
only active in its metabolized form (4-HOO-CPA). After activation in the liver 4-HOO-CPA is a 
strong alkylating drug, targeting proliferating cancer cells (reviewed by Fenselau [65]). In the 
in vitro experiments CPA was substituted by melphalan another alkylating drug which does 
not have to be metabolically activated. Additionally, cell death induction by cisplatin was 
analyzed, as SATB1 earlier had been shown to induce cisplatin resistance in hepatocellular 
carcinoma [64]. Cells were seeded in 96-well plates and expression of SATB1 was induced by 
50 nM doxycycline for 24 hours. Subsequently melphalan or cisplatin treatment was carried 
out. As shown in Figure 3-5 A SATB1 overexpression had no influence on the chemo-
sensitivity to melphalan in vitro. Cell death was provoked under induced and not induced 
conditions at the same level. In contrast, SATB1 overexpression altered the chemo-sensitivity 
against cisplatin. As shown in Figure 3-5 B SATB1 overexpressing cells were less sensitive to 
the cisplatin treatment than not induced cells. 
  
  
Results 
33 
 
 
Figure 3-5 Functional analysis of SATB1 overexpression PC3 SATB1 cell line 
Cells were seeded in 96-well plates. One day after seeding STAB1 expression was induced by 50 nM doxycycline 
for 24 hours. Subsequently chemotherapy, melphalan A. or cisplatin B., was applied for 72 hours. Cytotoxicity 
was determined by CellTiterGlo assay. Data is presented as percent of untreated control cells. *p < 0.05, **p< 
0.005, ***p<0.0005 (t-test) 
Similar experiments were performed using the PC3 ANXA3 cell line. Again the empty vector 
cell line (PC3 ev = empty vector) served as control. 
As shown in Figure 3-6 A the endogenous expression of ANXA3 mRNA and protein was 
already high. The induction by doxycycline increased the mRNA expression about 1.75-fold. 
In concordance, the expression on protein level was only increased marginally (Figure 3-6 B). 
Immuno-fluorescence imaging showed that ANXA3 was located in the cytoplasm of both 
ANXA3 induced and not induced cells (Figure 3-6 C). 
The functional analysis showed no alteration in chemo-sensitivity to neither melphalan nor 
cisplatin of ANXA3 overexpressing cells compared to not induced control cells (Figure 3-6 D 
and E).  
 
 
Figure 3-6 continued 
A. B. 
A. B. 
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Figure 3-6 Analysis of ANXA3 overexpression PC3 ANXA3 cell line 
A. qPCR of RNA B. western blot of protein lysates isolated from induced (24 hours, 50 nM doxycycline (+dox)) 
and not induced (control (-dox)) PC3 ANXA3 cells and PC3 ev (control) C. ANXA3 expression was induced using 
50 nM doxycycline and not induced (control) for 24 hours; blue = nuclei (Hoechst) green = ANXA3 (alexa 488). 
D. + E. ANXA3 expression was induced by 50 nM doxycycline for 24 hours. Thereafter, chemotherapy, 
melphalan or cisplatin, was applied for 72 hours. Cytotoxicity was determined by CellTiterGlo assay. Data is 
presented as percent of untreated control cells. 
C. 
D. E. 
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Taken together neither ANXA3 nor SATB1 alone were able to induce an in vitro resistance to 
the alkylating drug melphalan. Notably, a potential influence of ANXA3 or SATB1 
overexpression in vivo was not evaluated within the framework of this thesis. 
Further analysis was no longer focused on one special gene but more on the involvement of 
whole pathways and microenvironmental factors. 
3.1.3 Analysis of pathways involved in chemoresistance 
For further analysis different points were taken into account: 1) Resistant cell lines showed 
no in vitro resistance [13]. 2) The expression of in vivo regulated genes differed a lot from 
in vitro (Figure 3-1 and Figure 3-2). 3) No correlations of single target genes to resistance 
could be made in vitro (3.1.2). All these points lead to the hypothesis that the mechanism 
leading to chemoresistance to anti-angiogenic therapy are very complex, including the 
alteration of whole signaling pathways. 
To evaluate which pathways might be involved in resistance formation, a KEGG-pathway 
analysis was performed, including all genes with an expression change of 0.4 fold (up- and 
downregulated). This analysis revealed a potential involvement of three pathways: 1) axon 
guidance, 2) steroid biosynthesis and 3) complement and coagulation cascades (Figure 3-7). 
As blood flow might play a crucial role during resistance formation to anti-angiogenic 
therapy, further analysis was focused on the genes grouped in complement and coagulation 
cascades. In complement and coagulation cascades grouped genes included: tissue factor 
(F3), plasminogen activator tissue (PLAT), protein S (PROS), serine peptidase inhibitors A1 
and D1. After the analysis two differentially expressed coagulation genes annexin A3 
(ANXA3) and serine peptidase inhibitor clade B 7 (SERPINB7) were added to this group from 
the list of differentially expressed genes, as they are also reported to be correlated with 
coagulation. ANXA3 was shown to inhibit coagulation in vitro and SERPINB7 is a member of 
the serpins, a coagulation related protein-family [66, 67]. 
The expression pattern of the grouped genes was as follows: In resistant tissue the 
expression of coagulation related genes tissue factor (F3), plasminogen activator tissue 
(PLAT) and annexin A3 (ANXA3) was increased in resistant tumors, whereas the expression of 
protein S (PROS1), and serine proteinase inhibitors: SERPIND1, SERPINA1 and SERPINB7 was 
decreased (Table 3-1). 
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Figure 3-7 KEGG-Pathway analysis of regulated genes 
KEGG-Pathway analysis of differentially expressed genes (377 genes +/- 0.4 rel. expr. change)  
 
 
Table 3-1 Expression of complement and coagulation cascades associated genes 
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3.1.3.1 Gene expression of coagulation in resistant tumors 
To confirm the in the microarray predicted differential expression of coagulation related 
genes qPCR analysis was performed. Results are shown in Figure 3-8 as fold expression of 
control tumors (PC3 A3). The expression level of tissue factor was slightly increased. In 
PC3 D3 tumor tissue and in PC3 D4 tumor tissue F3 was highly expressed.  
 
Figure 3-8 Expression of coagulation related genes 
Validation of coagulation related gene expression by qPCR, SERPINA1 = serpin peptidase inhibitor clade A 
member 1, SERPIND1 = serpin peptidase inhibitor clade D member 1, SERPINB7 = serpin peptidase inhibitor 
clade B member 7, PROS1 = protein S (alpha), F3 = tissue factor, PLAT= plasminogen activator tissue and ANXA3 
= annexin A3 *p < 0.05 (t-test) 
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In contrast, SERPINA1 expression was reduced in resistant tumor tissue. In accordance, two 
potentially coagulation promoting genes SERPIND1 and SERPINB7 were downregulated in 
resistant tumors. Moreover, mRNA expression of proteins hampering coagulation PLAT and 
ANXA3 was increased in PC3 D3 and PC3 D4 tumor tissue compared to PC3 A3 control tissue 
(Figure 3-8). 
When analyzing the gene expression from in vitro cultured cell lines again a different pattern 
was observed: F3, PLAT, ANXA3 showed no altered gene expression in PC3 D3 and PC3 D4 
versus PC3 A3 (Figure 3-9), whereas the expression profile of SERPINA1, SERPIND1, SERPINB7 
and PROS1 were similar to that in vivo. 
In summary PLAT and ANXA3 that encode anti-coagulation proteins were upregulated and 
the SERPINs which are potentially promoting coagulation were downregulated in resistant 
tumor tissue, compared to in vivo passaged control tumors. These effects were not present 
in vitro. Interestingly, in contrast to the SERPINS the expression of pro-coagulation F3 gene 
was upregulated. 
 
 
 
Figure 3-9 continued  
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Figure 3-9 expression of coagulation related genes in vitro 
Expression of coagulation related genes in cell culture samples: SERPINA1 = serpin peptidase inhibitor clade A 
member 1, SERPIND1 = serpin peptidase inhibitor clade D member 1, SERPINB7 = serpin peptidase inhibitor 
clade B member 7, PROS1 = protein S (alpha), F3 = tissue factor, PLAT= plasminogen activator tissue and ANXA3 
= annexin A3 *p < 0.05 (t-test) 
 
3.1.3.2 F3 exon structure is altered in resistant PC3 D4 tumors  
F3 is a candidate which does not fit into the structure of an anti-coagulative status. F3 is 
highly upregulated in resistant tumors, but is a coagulation promoting gene. As shown in the 
introduction part (Figure 1-5), the exon structure of F3 was irregular. The microarray probe 
setup allows the expression of a single exon in detail. Comparing resistant PC3 D4 to in vivo 
passaged control PC3 A3 tissue, the exon expression profile of F3 shows an altered signal 
intensity between exon 3 and 6, whereas no differences were detected in exon 1 and 2 
(Figure 1-5). This indicates an expression of different F3 isoforms. Sequencing of the F3 gene 
transcript revealed no mutations in the coding sequence (data not shown). Thus it was 
hypothesized that two diverse transcripts of the F3 gene are present, one being prominently 
expressed in PC3 D4 tumors. To prove this finding, the expression levels of exon 1-2 and 
exon 5-6 were analyzed by qPCR respectively. In PC3 D4 a higher relative expression of exon 
5-6 compared to exon 1-2, providing evidence for the presence of two different F3 
transcripts (Figure 3-10 A) was observed. Western blot analysis of the F3 protein expressed 
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by PC3 D4 cell line when cultured in vitro compared to samples from tumor tissue directly 
reflects the qPCR results (Figure 3-10 B). In vitro PC3 D4 cells expressed low levels of F3 
protein, with a molecular weight of 47 kDa. On the contrary, in PC3 D4 tumor samples two 
types of F3 protein were observed, one with 47 kDa and another one with a lower molecular 
weight. The smaller F3 form is more abundant than the 47 kDa form (Figure 3-10 B).  
 
Figure 3-10 Analysis of F3 exon expression 
A. qPCR of exon 1-2 and exon 5-6 of F3 B. western blot analysis of F3 in resistant cell line PC3 D4 from in vitro 
cell culture samples and in vivo tumor samples 
Overall, it can be hypothesized that the additional short form of F3 missing exon 1 and 2 in 
resistant tumors is present in vivo. This shortening might lead to a loss of function, helping to 
maintain the anti-coagulative status. 
Taken together microarray analysis revealed a potential involvement of anti-coagulation in 
resistances formation upon metronomic CPA therapy. 
3.1.4 Anti-coagulation in vivo 
It could be shown that coagulation might be one of the pathways involved in resistance to 
metronomic CPA therapy. Anti-coagulation genes were upregulated and pro-coagulation 
genes were downregulated. To analyze if an anti-coagulative status contributes to resistance 
formation upon metronomic CPA treatment, the effect of warfarin was tested. Warfarin is an 
anti-coagulative drug.  
PC3 A3 cells were injected subcutaneously into the flanks of male SCID mice (5-7 per group). 
Two of in total four groups were treated with CPA (120 mg/kg every sixth day, i.p.) starting 
A. B. 
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at day 12 after tumor inoculation. The other two groups served as control. One of the CPA 
groups and one of the control groups were treated additionally with warfarin, starting at day 
11 after tumor inoculation. Until day 18, warfarin was applied over the drinking water. As 
mice stopped drinking around day 16 the treatment regimen was change to warfarin 5 
mg/kg i.p. every third day. Mice carrying tumors bigger than 1000 mm³ were euthanized. On 
day 57 the experiment had to be stopped due to severe weight loss. Analysis was carried out 
including only those 3 mice per group which lived until day 57, mice of the CPA treatment 
groups which had to be euthanized before day 57 were excluded. As shown in Figure 3-11 
CPA treatment significantly reduced tumor growth. Approximately at day 40 PC3 A3 tumors 
restarted growing. Warfarin had no significant effect on resistance formation. Comparing 
tumor sizes relative to day 11 warfarin and CPA treated tumors are growing slightly but not 
significantly faster than CPA treated tumors without warfarin administration (Figure 3-11).  
 
 
 
Figure 3-11 PC3 A3 tumor growth in vivo 
Growth of PC3 A3 s.c. tumors over time. A. tumor volume B. percent of tumor volume on day 11 
In summary, it could be shown that resistance to metronomic therapy is a complex 
mechanism. Neither overexpression of ANXA3 nor SATB1 (both genes were upregulated in 
resistant tissue) were able to provoke an in vitro resistance. Moreover, the involvement of 
whole pathways and signaling cascades in resistance formation was shown. In particular, the 
pathway of complement and coagulation cascades was shown to be altered in resistant 
tissue. Up to now this involvement could not been proved in vivo, as warfarin, an inhibitor of 
coagulation did not accelerate resistance to metronomic CPA therapy in a first in vivo 
experiment.  
A. B. 
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3.2  Characterization of archazolid action on the secretion profile of 
eukaryotic cells 
In cancer the V-ATPase plays a pivotal role. It can be located on the plasma membrane as 
well as on intracellular membranes like the lysosome membrane. The V-ATPase is an ATP 
dependent proton pump and pumps protons out of the cell or into lysosomes. Thus it 
maintains the intracellular pH and acidifies endosomes and prelysosomal compartments.  
It is known from literature that V-ATPase inhibition strongly alters exo- and endocytotic 
events by interfering intracellular trafficking [68, 69]. As the microenvironment plays an 
important role in cancer progression the influence of archazolid, a novel V-ATPase inhibitor, 
on the secretion profile of eukaryotic cells was evaluated. Therefore, the protein abundance 
in supernatants of archazolid treated highly migratory [70] human urinary bladder carcinoma 
cells and primary human monocytes were analyzed by LC-MS/MS. 
All LC-MS/MS measurements were performed in cooperation with Dr. Thomas Froehlich and 
Dr. Georg J. Arnold (Genzentrum, LMU Munich, Germany). 
3.2.1 Secretome analysis of archazolid treated monocytes 
As mentioned before the microenvironment plays a crucial role in cancer progression. 
Especially, the influence of the immune system is critical, as it can defeat and actively kill 
tumor cells as well as promote tumor growth. To get a first insight, which proteins are 
secreted from primary human monocytes a qualitative analysis was performed. Monocytes 
were treated with 10 nM archazolid for 24 hours in serum free media. To promote the 
secretion of pro-inflammatory cytokines, stimulation with lipopolysaccharides (LPS) was 
performed simultaneously. Supernatants were collected, concentrated and separated using 
SDS-PAGE (Figure 3-12 A). The coomassie stained gel shows a slightly stronger staining in 
lanes C and D compared to the control in lane A and B which leads to a first assumption that 
an increased amount of proteins was secreted during archazolid treatment. In contrast, an 
alteration of the secretion profile by LPS was not visible on the gel. Furthermore, one can 
estimate that the fetal calf serum (FCS) contamination was neglect able, as the serum 
albumin signal around 60 kDa was in the appropriate intensity. To identify the present 
proteins, lanes were cut into 10 pieces and analyzed using LC-MS/MS. 
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In total 152 proteins were identified. Further, an analysis of the cellular components of the 
identified genes using uniprot.org identified 17% as secreted proteins. The majority was 
identified as intracellular proteins (Figure 3-12 B). Notably, identification of secreted 
proteins is strongly depended on the algorithm applied by the used software. Thus, the 
assignment of the identified proteins to cellular compartments only served to get a first 
insight to the data (Figure 3-12 B). Furthermore a KEGG-Pathway analysis using DAVID 
bioinformatics indicated the involvement of different pathways. The five most enriched are: 
1) regulation of the actin cytoskeleton, 2) glycolysis and gluconeogenesis, 3) leukocyte 
transendothelial migration, 4) focal adhesion and 5) systemic lupus erythematosus (Figure 
3-12 C). 
 
 
 
Figure 3-12 LC-MS/MS Analysis of secreted proteins 
A. 5 x 10
6
 human primary monocytes were seeded per 75 cm
2
 cell culture flasks and treated with 10 nM 
archazolid (lanes C and D) or 0.01% DMSO as control (lanes A and B). LPS stimulation was done using 1 µg/ml 
(lanes A and C). Supernatants were collected after 24 hours, concentrated and SDS-PAGE was performed using 
a 12.5% gel. After electrophoresis each lane was cut into 10 similar pieces. A total number of 152 proteins were 
identified. Identified proteins were analyzed using uniprot.org and DAVID bioinformatics. B. Cellular 
component of identified proteins C. KEGG-Pathway analysis of identified proteins, p-values equal or smaller 
than 0.05 were considered as strongly enriched. 16 pathways were identified as strongly enriched. Shown are 
the 5 pathways with the highest count numbers. 
A. B. 
C. 
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In a second approach secreted proteins of human monocytes were quantified using the 
iTRAQ (Isobaric tag for relative and absolute quantitation) method (Figure 3-13). Here, 
protein abundance in a given sample can be quantified using an isotope-coded covalent tags 
(reviewed by Zieske, 2006 [71]. 
 
Figure 3-13 Chemical structure of the iTRAQ-label 
The iTRAQ-label contains an isobaric tag consisting of a charged reporter group, a peptide reactive group, and a 
neutral balance portion to maintain an overall mass of 145 [71].  
 
Human primary monocytes activated with LPS (lipopolysaccharides) were treated with 
10 nM archazolid for 24 hours or not treated. Protein abundance in the respective 
supernatants was analyzed. Three LC-MS/MS measurements, comparing one treated sample 
with one control sample were performed. In Table 3-2 results of all three measurements are 
shown. A cut off of 0.4 relative differences in abundance was set. Although all samples were 
prepared simultaneously, differences in relative abundance appeared very diverse within the 
measurements.  
To draw further conclusions western blot validation has to be performed in future 
experiments. Potential candidates for validation may be: 1) thrombospondin 1 
(TSP1_HUMAN) as it is differentially abundant in all three samples, 2) interleukin 6 and 8) 
interleukin 8 as they are both cytokines involved in monocyte mediated signal transduction.  
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Table 3-2 Relative quantification (iTRAQ) of secreted proteins 
withe background: less abundant, gray= more abundant  
Sample 7_5 
 
Sample 7_6 
 
Sample 7_7 
# Accession Number rel. a  
 
# Accession Number rel. a  
 
# Accession Number rel. a 
1 ALBU_HUMAN -1,3 
 
1 VIME_HUMAN -1,4 
 
8 TSP1_HUMAN -1,9 
2 ACTB_HUMAN  -0,9 
 
2 MOES_HUMAN -1,2 
 
98 ANXA6_HUMAN -1,7 
3 VIME_HUMAN -0,6 
 
3 PROF1_HUMAN -1 
 
40 IL6_HUMAN -1,4 
4 ENOA_HUMAN -0,6 
 
4 ACTB_HUMAN  -1 
 
72 K2C1_HUMAN -1,4 
5 PROF1_HUMAN -0,6 
 
5 ENOA_HUMAN -1 
 
31 PAI2_HUMAN -1 
6 TSP1_HUMAN -0,4 
 
6 MYH9_HUMAN -0,8 
 
58 IL8_HUMAN -1 
7 TPIS_HUMAN -0,4 
 
7 PLSL_HUMAN -0,7 
 
45 S10A8_HUMAN -0,8 
   
 
8 FLNA_HUMAN -0,7 
 
53 CLIC1_HUMAN -0,7 
   
 
9 ALBU_HUMAN -0,7 
 
27 S10A9_HUMAN -0,5 
   
 
10 TSP1_HUMAN -0,6 
 
28 CXCL7_HUMAN -0,5 
   
 
11 K2C1_HUMAN -0,6 
 
41 TLN1_HUMAN -0,5 
   
 
12 H4_HUMAN -0,6 
 
46 COF1_HUMAN -0,5 
   
 
13 1433Z_HUMAN -0,6 
 
23 H2B1C_HUMAN  -0,4 
   
 
14 TKT_HUMAN -0,6 
 
71 H31T_HUMAN  -0,4 
   
 
15 ALDOA_HUMAN -0,6 
 
   
    
16 LYSC_HUMAN -0,6 
 
   
    
17 ACTN4_HUMAN -0,5 
 
   
    
18 G6PI_HUMAN -0,5 
 
   
    
19 H2B1C_HUMAN  -0,5 
 
   
    
20 ANXA1_HUMAN -0,4 
 
   
    
21 COR1A_HUMAN -0,4 
 
   
    
22 K1C10_HUMAN -0,4 
 
   
    
23 S10AB_HUMAN -0,4 
 
   
    
24 HSP7C_HUMAN -0,4 
 
   
    
25 TALDO_HUMAN -0,4 
 
   
27 ITAM_HUMAN 0,4 
 
78 H12_HUMAN  0,4 
 
17 1433Z_HUMAN 0,4 
28 MYH9_HUMAN 0,4 
 
79 HEXB_HUMAN 0,4 
 
33 GDIR2_HUMAN 0,4 
29 PRDX1_HUMAN 0,4 
 
80 HNRH1_HUMAN 0,4 
 
67 PPIB_HUMAN 0,4 
30 SH3L3_HUMAN 0,5 
 
81 KCD12_HUMAN 0,5 
 
93 SH3L1_HUMAN 0,4 
31 TPM3_HUMAN 0,6 
 
82 LEG1_HUMAN 0,5 
 
32 HSP71_HUMAN 0,5 
32 TALDO_HUMAN 0,6 
 
83 LKHA4_HUMAN 0,5 
 
36 H14_HUMAN 0,5 
33 ELNE_HUMAN 0,6 
 
84 PPIB_HUMAN 0,9 
 
65 PERM_HUMAN 0,5 
34 DEF1_HUMAN  0,7 
 
85 SHPS1_HUMAN  0,9 
 
70 CATS_HUMAN 0,5 
    
86 STMN1_HUMAN 0,9 
 
82 FETUA_HUMAN 0,5 
    
87 SUMO2_HUMAN 1 
 
75 TAGL2_HUMAN 0,7 
    
88 THIO_HUMAN 1 
 
88 NPC2_HUMAN 0,8 
    
89 ANXA2_HUMAN 1,1 
 
84 G3P_HUMAN 0,9 
    
90 CATS_HUMAN 1,1 
 
90 PLBL1_HUMAN 1,3 
    
91 NUCL_HUMAN 1,4 
 
38 SAP_HUMAN 1,4 
    
92 PAI2_HUMAN 1,5 
    
    
93 B2MG_HUMAN 1,7 
    
    
94 CALR_HUMAN 6,2 
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Additional to the proteomic analysis of monocytes supernatants, corresponding cell lysates 
were analyzed by western blot. Furthermore, human primary monocytes were differentiated 
into macrophages and treated with 10 nM archazolid for 4 hours. As it will be shown in the 
following chapters, abundance of the lysosomal protease and tumor marker cathepsin B is 
strongly altered by archazolid treatment. Thus, cathepsin B protein in cell lysates of 
macrophages and monocytes was analyzed by western blot. As shown in Figure 3-14 
cathepsin B protein was not detectable in monocytes. In contrast in macrophages 
cathepsin B was strongly expressed. Here archazolid treatment significantly reduced the 
amount of mature cathepsin B. 
 
 
 
Figure 3-14 Cathepsin B secretion of primary human monocytes and macrophages 
A. Human primary monocytes were treated with 10 nM archazolid = archB, lysosomotropic agent chloroquine = 
CQ (10 µM) or control treated with 0.01% DMSO. LPS stimulation was done using 1 µg/ml. Cells were lysed 
after 24 hours, concentrated and western blot analysis of cathepsin B was performed. B. Human primary 
macrophages were seeded in cell culture flasks and treated with 10 nM archazolid (n=3) or with 0.01% DMSO 
(n=3). Cells were lysed after 4 hours (macrophages), concentrated and western blot analysis of cathepsin B was 
performed. proCTSB = procathepsin B, mCTSB = mature cathepsin B 
  
A. B. 
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3.2.2 Secretome analysis of archazolid treated urinary bladder carcinoma cells 
After analyzing the influence of archazolid on immune cells it was analyzed how V-ATPase 
inhibition by archazolid alters the secretion profile of migratory cancer cells. Thus, in a first 
experiment the secretion profile of archazolid treated T-24 (urinary bladder carcinoma cells), 
was determined. Therefore, supernatants of archazolid treated and control treated T-24 
cells were collected and concentrated. A concentration of 1 nM archazolid was chosen as no 
cytotoxicity was detected for this concentration after 24 hours in FCS free media (Figure 3-15 
B). Moreover, a staining of acidic compartments using the lysotracker reagent showed that 
starting with a concentration of 1 nM archazolid the size and distribution of acidic 
compartments is altered. At a concentration of 10 nM no lysotracker staining was 
detectable, indicating that lysosomes are no longer acidic (Figure 3-15 C). In concordance 
immunofluorescence staining of the lysosomal marker protein (lamp1) shows and altered 
lamp1 protein distribution already at 1 nM archazolid (Figure 3-19).  
 
 
 
 
Figure 3-15 continued 
 
A. B. 
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Figure 3-15 Analysis of archazolid treated T-24 cells 
A. 1.5 x 10
6
 T-24 cells were seeded in cell culture flasks and treated with 1 nM archazolid for 24 h. Supernatants 
were collected, concentrated and SDS-PAGE was performed using a 12.5% gel. After electrophoresis each lane 
was cut into 10 similar pieces. B. CellTiterGlo-Assay of T-24 cells after 24 hours of treatment, STS = 
staurosporine (positive control). C. lysotracker staining of archazolid treated (1 nM and 10 nM for 24 hours) 
T-24 cells.  
Thus, T-24 cells were treated 24 hours with 1 nM archazolid for analysis of the secretion 
profile. Supernatants were collected and concentrated. In the following, proteins were 
separated using SDS-PAGE (12.5%) and each lane was cut into 10 pieces (Figure 3-15 
A).Proteins were reduced, alkylated and digested with trypsin by in-gel-digestion (2.2.9.1), 
prior to LC-MS/MS analysis. 
Identified proteins were analyzed using uniprot.org and DAVID bioinformatics. Analysis of 
cellular component showed that 26% of all identified proteins were mapped into the 
category of secreted cellular component (Figure 3-16 A). Furthermore, KEGG-Pathway 
analysis showed the enrichment of 16 pathways. The five carrying the highest count 
numbers are shown in Figure 3-16 B. 
  
C. 
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Figure 3-16 LC-MS/MS analysis of secreted proteins 
A total number of 374 proteins were identified. Identified proteins were analyzed using uniprot.org and DAVID 
bioinformatics. A. Cellular component of identified proteins B. KEGG-Pathway analysis of identified proteins: 16 
pathways were identified as strongly enriched. Shown are the 5 pathways including the highest count-
numbers. p-values equal or smaller than 0.05 were considered. In the included table on the right identifiers of 
the pathway lysosome are listed. 
Namely, the five most enriched pathways were 1) focal adhesion, 2) ECM-receptor 
interaction, 3) Regulation of actin cytoskeleton, 4) Ribosome and 5) Lysosome. As it is known 
from literature that V-ATPase inhibitor bafilomycin induces lysosomal enzyme secretion in 
macrophages and lysosomal proteases are correlated with enhanced invasion further 
analysis was focused on the lysosomal pathway. Identified proteins annotated in the 
A. 
B. 
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category lysosome are shown in Figure 3-16 B, right table. Especially members of the 
cathepsin family were prominent in the secretion profile. Therefore quantification by 
western blot was performed for cathepsin B and cathepsin D. Both proteins are tumor 
makers and potentially involved in metastatic processes [42, 45]. T-24 cells were treated 
with archazolid in FCS free media and supernatants were collected after 24 hours. 
Thereafter, samples were concentrated and western blot was performed. As shown in Figure 
3-17 both proteins were significantly more abundant in supernatants of archazolid treated 
cells. Signals indicated that not the active enzymes (25 kDa cathepsin B and 28 kDa 
cathepsin D) but the inactive and larger preforms (41 and 46 kDa) were secreted. 
 
 
 
Figure 3-17 Western blot analysis of secreted cathepsin B and cathepsin D 
Supernatants of archazolid treated T-24 cells (-FCS, 1 nM archazolid, 24 hours) and control supernatants (-FCS, 
DMSO, 24 hours) were collected. After SDS-Page gels were blotted on a nitrocellulose membrane and probed 
with either anti-cathepsin B or anti-cathepsin D specific antibodies. 
To prove that the secretion of procathepsin B and not of mature cathepsin B was induced by 
archazolid, supernatants of treated T-24 cells were separated by SDS-PAGE. The part where 
the signals of the western blot appeared around 41 kDa was excised from the coomassie 
stained gel and proteins in this fraction analyzed by LC-MS/MS. As shown in Figure 3-18 a 
peptide was identified, which is part of the propeptide of cathepsin B proving that 
procathepsin B is the prominent secreted form during archazolid treatment. 
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Figure 3-18 Identification of procathepsin B by qualitative LC-MS/MS 
Supernatants of archazolid treated T-24 cells were separated by SDS-PAGE, a section of the coomassie stained 
cell around >37 kDa (where the signals of the western blot appear) was excised, digested and subjected to 
LC-MS/MS. Source of sequence data: uniprot.org 
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3.3 Lysosome inhibition by archazolid in cancer cells 
Since the secretome analysis showed that archazolid strongly alters the fate of lysosomal 
proteins and induces the secretion of their proforms, in the following the influence of 
lysosome inactivation by archazolid on urinary bladder carcinoma cells was analyzed. 
As previously shown, archazolid neutralizes lysosomes by V-ATPase inhibition similar to 
other V-ATPase inhibitors like bafilomycin or concanamycin [29, 30]. 
Furthermore, an immuno-fluorescence staining of lamp1 (Lysosomal-associated membrane 
protein 1) protein showed that the enlarged lamp1 containing structures, which were earlier 
described as a result of concanamycin and bafilomycin treatment [68] arise also after 
archazolid treatment (Figure 3-19). Lysosome marker lamp1 is located on relatively small 
vesicles in untreated T-24 cells. After 24 hours of 1 nM archazolid the lamp1 signals appear 
in bigger vesicular compartments, which are even larger when cells were treated with 10 nM 
archazolid.  
Taken together archazolid induced inactivation of V-ATPase led to neutralization of the 
lysosomes (Figure 3-15 C) and to the formation of mega-lysosomal compartments (Figure 
3-19). 
 
 DAPI    lamp1 
 
Figure 3-19 Immuno-fluorescence imaging of lamp1 protein 
T-24 cells were seeded on cover slips in 6-well plates. Cells were treated for 24 hours with 1 nM and 10 nM 
archazolid, fixed and immuno-fluorescence imaging of lamp1 (green) was performed. 
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3.3.1 Concentration and time dependent secretion of procathepsin B 
Archazolid induced the secretion of procathepsin B. Thus, in this chapter the archazolid 
induced secretion of procathepsin B was analyzed more in detail. 
First T-24 cells (urinary bladder carcinoma) as well as a second cancer cell line MCF-7 (breast 
cancer) were treated with increasing concentrations of archazolid. Procathepsin B secretion 
was monitored by western blot analysis of cathepsin B in concentrated supernatants. After 
24 hours procathepsin B secretion by T-24 cells was detected starting at a concentration of 
0.5 nM archazolid (Figure 3-20 A, upper panel). MCF-7 cells secreted detectable amounts of 
procathepsin B at 1 nM of archazolid (Figure 3-20 A, lower panel). 
To evaluate the secretion kinetics, T-24 and MCF-7 cells were treated for extended time 
periods with 1 nM archazolid. Both T-24 and MCF-7 cells secreted detectable amounts of 
procathepsin B after 5 hours of archazolid treatment. Procathepsin B accumulated in the 
supernatants over time (Figure 3-20 B). 
 
Figure 3-20 Western blot analysis of supernatants of archazolid treated cells 
A. T-24 cells or MCF-7 cells were treated with 0.1 nM, 0.5 nM, 1 nM and 10 nM archazolid for 24 hours, 
supernatants were collected, concentrated and western blot was performed. B. T-24 cells or MCF-7 cells were 
treated with 1 nM archazolid; supernatants were collected after 2, 5, 10 and 24 hours, concentrated and 
western blot was performed. proCTSB = procathepsin B 
Taken together, archazolid induced procathepsin B secretion was concentration and time 
dependent in both cell lines. In general, detected effects were stronger in T-24 cells than in 
MCF-7 cells.  
A. B. 
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3.3.2 Reduction of intracellular cathepsin B activity by archazolid 
Previously it was shown that archazolid induces the secretion of lysosomal proenzymes 
procathepsin B and procathepsin D. To evaluate the intracellular fate of different cathepsin B 
forms during V-ATPase inhibition, T-24 cells were treated with increasing concentrations (0.1 
– 10 nM) of archazolid for 24 hours and cell lysates were analyzed by western blot (Figure 
3-21 A). As it is shown in Figure 3-21 A the abundance of procathepsin B (41 kDa) increased, 
whereas the amount of mature cathepsin B (heavy chain, 25 kDa) decreased with increasing 
archazolid concentrations. Also the amount of mature cathepsin D decreased while the 
proform of cathepsin D increased. Furthermore, the mRNA expression of cathepsin B and 
cathepsin D was evaluated. qPCR analysis showed that the mRNA of cathepsin B and 
cathepsin D was more than 3-fold increased in archazolid treated T-24 cells (Figure 3-21 B). 
 
Figure 3-21 Cathepsin B expression 
A. T-24 cells were treated with 0.1, 0.5, 1 and 10 nM archazolid or mock treated with DMSO (control). Cells 
were lysed after 24 hours of treatment proCTSB/D = procathepsin B/D, mCTSB/D = mature cathepsin B/D; 
B. T-24 cells were treated with 1 or 10 nM archazolid or mock treated for 24 hours. Cathepsin B and 
cathepsin D mRNA expression was determined using qPCR. 
A. B. 
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To investigate the cellular distribution of cathepsin B immunofluorescence imaging of 
intracellular cathepsin B (all cathepsin B forms) was performed. As shown in Figure 3-22 
cathepsin B was primarily located in small vesicular compartments in control cells. These 
compartments appeared larger at a concentration of 1 nM archazolid. Even larger, 
cathepsin B positive vesicular compartment were detected after archazolid treatment of 
10 nM. 
 
Figure 3-22 Immuno-fluorescence imaging of cathepsin B 
T-24 cells were seeded on cover slips in 6-well plates. Cells were treated for 24 hours with 1 nM and 10 nM 
archazolid, fixed and immuno-fluorescence cathepsin B (green) was performed. 
Since western blot analysis showed that archazolid induced a dramatic decrease of mature 
cathepsin B (Figure 3-21 A), the proteolytic activity of cathepsin B in archazolid treated cell 
lysates was evaluated by a cathepsin B activity assay (2.2.1). In Figure 3-23 it is shown that 
archazolid significantly reduced the cathepsin B activity down to less than 40% of the 
control. 
 
Figure 3-23 Cathepsin B activity in cell lysates  
T-24 cells were treated with 1 or 10 nM archazolid or were mock treated with DMSO (control). After 24 hours 
cells were lysed. The relative cathepsin B activity in 30 µg (total protein) of each lysate was determined. *p < 
0.05, **p< 0.005, (t-test) 
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In summary, archazolid treatment reduced the amount of intracellular mature cathepsin B, 
which resulted in a decreased cathepsin B proteolytic activity. Concomitantly, the mRNA 
level of cathepsin B increased during archazolid treatment. 
3.3.3 Effects on cathepsin B by V-ATPase V0c silencing 
To estimate if the altered cathepsin B abundance was a direct effect of the inhibition of 
V-ATPase, the target of archazolid, the V0c subunit, was silenced by RNAi. 
Analyzing V0c mRNA expression 24 and 48 hours after transfection, a clear knockdown of 
subunit V0c was detectable (Figure 3-24 A). Similar to archazolid treatment, silencing of 
subunit V0c induced cathepsin B mRNA expression (Figure 3-24 B). 
Western blot analysis of supernatants of V0c silenced cells showed an induced 
procathepsin B secretion (Figure 3-24 C), while in whole cell lysates intracellular mature 
cathepsin B was reduced in V0c -siRNA treated samples. Procathepsin B was slightly elevated 
in V0c-siRNA treated cells compared to the noncoding control (Figure 3-24 D).  
 
 
Figure 3-24 continued 
A. B. 
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Figure 3-24 Effect of V-ATPase knockdown on mRNA and protein level 
T-24 cells were transfected either with siRNA against V0c or control siRNA. Cells were lysed 24 or 48 hours after 
transfection. A. Sufficient knockdown was monitored by qPCR of V-ATPase subunit V0c. B. Expression of 
cathepsin B mRNA during V0c knockdown was analyzed by qPCR. C. procathepsin B secretion and D. 
intracellular cathepsin B after 24 hours was analyzed by western blot. **p< 0.005, ***p<0.0005 (t-test) 
In summary, the described archazolid effects on cathepsin B expression could be mimicked 
by silencing of the archazolid target domain (V0c) of the V-ATPase by RNAi. 
3.3.4 Procathepsin B secretion is induced by lysosome neutralization  
In the previous chapter it was shown that the archazolid effects on cathepsin B expression 
arise from V-ATPase inhibition. Therefore it was analyzed if other V-ATPase inhibitors exhibit 
similar effects on procathepsin B secretion. Thus, T-24 cells were treated with the following 
V-ATPase inhibitors: 1) bafilomycin A1 and 2) concanamycin A. 
Analyzing the supernatants of bafilomycin and concanamycin T-24 cells for cathepsin B 
abundance by western blot analysis, an elevated procathepsin B secretion was detected in 
bafilomycin and concanamycin treated samples but not in supernatants of control treated 
cells. As a second control T-24 cells were treated with DNA-intercalator doxorubicin (Figure 
3-25). Neither 5 nM nor 10 nM doxorubicin did induce procathepsin B secretion after 
24 hours. Similar results were obtained for cathepsin D. 
C. D. 
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Figure 3-25 Induction of procathepsin B secretion by different V-ATPase inhibitors  
T-24 cells were treated with 1 nM archazolid = archB, 1 nM concanamycin A = concA, 1 nM bafilomycin A1 
=bafA1, 0.01% DMSO = control or 5 and 10 nM doxorubicin = DXR for 24 hours. Supernatants were collected, 
concentrated and western blot was performed.  
These results indicate that archazolid induced reduction of mature cathepsin B and induced 
procathepsin B secretion is caused by hampered lysosome function. Due to the fact that 
V-ATPase inhibition leads to the neutralization of the lysosome [29], it was evaluated 
whether the detected secretion of procathepsin B in T-24 cells by archazolid was a result of 
lysosome neutralization. For this purpose, cells were treated with lysosomotrophic agents: 
chloroquine and NH4Cl. In both cases procathepsin B secretion was detected in the 
supernatants (Figure 3-26). 
 
Figure 3-26 Induction of procathepsin B secretion by lysosomotropic agents  
T-24 cells were treated with lysosome disruption agents NH4Cl (5 mM) and chloroquine = CQ (20 µM) for 24 h. 
Supernatants were collected, concentrated and western blot was performed. 
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3.3.5 M6PR-dependent transport of procathepsin B to the lysosome 
In the previous chapters it could be shown that archazolid induced procathepsin B secretion 
and intracellular mature cathepsin B reduction is a result of lysosome neutralization by 
V-ATPase inhibition. To analyze in detail how archazolid action interferes with the 
cathepsin B maturation process further experiments were performed. 
It is known from literature that procathepsin B transport to pre-lysosomal compartments is 
mediated through the mannose-6-phosphate receptor (M6PR) [57]. After glycosylation in 
the Golgi apparatus, procathepsin B is bound to M6PR in the trans-Golgi network (TGN). 
M6PR containing vesicles are then fusing with prelysosomal compartments (PLC). After 
acidification of the PLC, M6PR can release its cargo and recycles to the TGN. M6PR cannot 
release its cargo if the pH of the compartment is too high [72]. As archazolid strongly raises 
the lysosomal pH by inhibiting V0c of the V-ATPase it was hypothesized based on the 
literature that bound procathepsin B cannot be released by the M6PR, when the lysosomal 
pH is elevated by archazolid action. As a result, no new mature cathepsin B can be generated 
and existing mature cathepsin B loses its activity in a non-acidic environment. The lack of 
cathepsin B might lead to an increased transcription of cathepsin B mRNA resulting in a 
procathepsin B overload, as new translated preprocathepsin B can be converted into 
glycosylated procathepsin B but cannot be subjected to M6PR mediated transport, which 
leads to the secretion of procathepsin B (schematically summarized in Figure 3-27 A. 
In order to prove this hypothesis, T-24 cells were treated with tunicamycin, an inhibitor of 
N--acetylglucosamine transferase which is part of the glycosylation process of lysosome 
targeted proteases [73]. As shown in Figure 3-27 B tunicamycin induces the secretion of a 
slightly smaller version of procathepsin B, indicating that blocking of the glycosylation 
process also impairs the M6PR mediated transport, resulting in secretion of procathepsin B 
in an unglycosylated form. Unglycosylated procathepsin B will not be bound to the M6PR as 
it lacks the tagging-sequence.  
Additionally, the transport from the endoplasmatic reticulum to the Golgi app. was inhibited 
by brefeldin. As shown in Figure 3-27 B treatment of T-24 cells using brefeldin fully blocked 
the archazolid induced procathepsin B secretion, as procathepsin B could not be transported 
to the Golgi app.. 
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Figure 3-27 Effect of tunicamycin and brefeldin on procathepsin B secretion 
A. schematically overview of the cathepsin B maturation process B. T-24 cells were treated either with 
tunicamycin = tunm (5 µg/ml), archazolid = archB (5 nM), brefeldin = bref or a combination of brefeldin = 
bref+archB (5 µg/ml) and archazolid (5 nM) for 24 hours.  
To visualize the archazolid induced impaired M6PR-trafficking immuno-fluorescence staining 
of M6PR was carried out (Figure 3-28). Archazolid treatment strongly altered the M6PR 
distribution in the cell, indicating an impaired recycling process. In untreated T-24 cells 
M6PR signals were distributed all over cell, concentrating in a nucleus associated region. In 
contrast, in archazolid treated cells M6PR signals were detected in vesicular compartments 
evenly distributed all over the cell (Figure 3-28). 
A. 
B. 
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Figure 3-28 continued  
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Figure 3-28 Immuno-fluorescence imaging of M6PR and cathepsin B 
T-24 cells were seeded on cover slips and treated with 1 nM and 10 nM archazolid for 24 hours. Cells were 
fixed and immuno-fluorescence was performed using antibodies against cathepsin B (green) and M6PR (red). 
Nuclei were stained using Hoechst dye (blue). 
In summary these results show that V-ATPase inhibition by archazolid impairs M6PR 
mediated trafficking from the TGN to prelysosomal compartments, resulting in a decrease of 
active lysosomal proteases like cathepsin B. 
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3.4 Action of archazolid and other myxobacterial compounds in vivo 
To evaluate if the detected archazolid action on cathepsin B maturation was also present 
in vivo, tumor bearing mice were treated with archazolid. These experiments were 
performed in cooperation with Laura Schreiner (PhD thesis 2013, LMU). In a first experiment 
two other myxobacterial compounds 1) pretubulysin and 2) chondramid B were included. 
An syngenic mouse model using mouse mammary gland tumor cells (4T1luc) stably 
expressing luciferase as a reporter gene was applied to analyze archazolid, pretubulysin and 
chondramid B action on tumor growth in vivo. 4T1luc cells were injected into the flank of 
BALB/c mice. Starting at day 3 after tumor injection, mice were treated 3 times per week i.v. 
with 3 mg/kg archazolid, 0.1 mg/kg pretubulysin, 0.5 mg/kg chondramid B or vehicle control 
(5% DMSO in PBS). None of the 3 substances reduced the growth of the main tumor 
significantly (Figure 3-29 A). Except that archazolid injection induced local cutaneous 
inflammation at the tail injection site, when not been totally injected intravenously, no acute 
toxicity of archazolid, pretubulysin or chondramid B was noticed during the treatment. Mice 
were euthanized on day 18 subsequently to tumor injection (after a total of 7 treatments).  
 
Figure 3-29 In vivo effect of myxobacterial compounds 
4T1luc cells were injected into the flanks of BALB/c mice. Starting on day 3, mice were treated 3 times per week 
i.v. with 3 mg/kg archazolid, 0.1 mg/kg pretubulysin, 0.5 mg/kg chondramid B or vehicle control (5% DMSO in 
PBS). On day 18 mice were euthanized. A. tumor growth B. ex vivo luciferase signal of the lungs on day 18 
None of the three substances exhibited a direct effect on tumor growth in this model. As it 
was known from literature, that 4T1 cells form metastases [74], distant metastases in the 
lungs were detected by the measurement of the luciferase signal. Although obtained results 
A. B. 
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were statistically not significant, lungs of mice which were treated with pretubulysin or 
archazolid showed less metastatic burden (Figure 3-29 B). 
A second experiment was focused on archazolid action on cathepsin B maturation. Again 
4T1luc cells were injected into the flanks of BALB/c mice. Starting at day 3 after tumor 
injection, mice were treated 3 times per week i.v. with 3 mg/kg archazolid. On day 16 mice 
were euthanized, tumors, and organs (lung, heart, kidney, spleen and liver) were harvested. 
Again archazolid treatment did not reduce tumor growth of 4T1luc cells (Figure 3-30 A). 
Furthermore, tumors showed no significant differences in morphology (Figure 3-30 B). 
 
Figure 3-30 Archazolid treatment of s.c. 4T1luc tumors in vivo 
4T1luc cells were injected into the flanks of BALB/c mice. At day 2, 3, 4 , 5, 9, 13 and 17 mice were treated with 
3 mg/kg archazolid or vehicle control (5% DMSO in PBS). On day 18 mice were euthanized. A. tumor growth 
and B. H&E stain of the tumor tissue 
To determine systemic archazolid action cathepsin B activity in livers of archazolid treated 
versus mock treated mice was analyzed. As shown Figure 3-31 A cathepsin B activity in the 
liver was strongly reduced by archazolid. To further evaluate if archazolid impaired also 
tumor cathepsin B, its activity in tumor lysates was determined. As shown in Figure 3-31 B, 
cathepsin B activity was reduced in tumors of archazolid treated mice. In accordance mature 
cathepsin B protein was reduced in the treatment group (Figure 3-31 C). Also in this 
experiment metastatic burden of the lungs was slightly but not significantly reduced in the 
archazolid treated group (Figure 3-31 D). 
In correspondence with in vitro results of 4T1luc cells cathepsin B mRNA expression was 
slightly, however not significantly induced (Figure 3-32).  
A. B. 
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Figure 3-31 Archazolid action on cathepsin B activity in vivo 
A. relative cathepsin B activity of the liver B. relative cathepsin B activity of the tumor *p < 0.05 (t-test) C. 
western blot analysis of tumor samples D. ex vivo luciferase activity measurement of the lungs (n=10). Whole 
lungs were homogenized and luciferase activity of metastasized 4T1luc cells of each sample was determined. 
Significant outlier were removed using Grubbs' test (alpha = 0.05). 
 
Figure 3-32 Cathepsin B mRNA expression of 4T1luc cells 
A. RNA of 30 µg of 5 tumors per group was isolated and cDNA was transcribed. qPCR was performed analyzing 
cathepsin B mRNA expression. B. Archazolid treatment of 4T1luc cells using 1 and 10 nM was performed for 24 
hours. RNA was isolated and cDNA was transcribed. qPCR was performed analyzing cathepsin B mRNA 
expression. 
A. B. 
C. D. 
A. B. 
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In summary, in vitro results were confirmed in vivo, as archazolid treated mice showed a 
reduced amount of cathepsin B protein in tumor tissue as well as a decreased proteolytic 
cathepsin B activity. Furthermore, a functional effect of archazolid on the formation of 
distant metastasis was detected. In two experiments archazolid treated mice exhibited a 
lesser metastatic burden in the lungs as control treated mice. 
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4 Discussion 
4.1 Resistance formation upon metronomic cyclophosphamide therapy 
Cells developing resistance to metronomic cyclophosphamide (CPA) therapy undergo a 
complex molecular evolution. Changes in many different factors and pathways contribute to 
the formation of a resistant phenotype. Metronomically administered CPA acts anti-
angiogenically on tumor vessels, whereas CPA given in standard dose is mainly acting on the 
tumor itself [11-13, 75]. Most of the classical resistance mechanisms can be ruled out in the 
present study (Figure 1-2). Neither increased MDR-transporter activity, nor neo 
angiogenesis, vascular mimicry or impaired CPA activation was observed (Figure 1-2 and 
[13]). Additionally a pharmacodynamic study of metronomically administered CPA suggests 
that it is unlikely that resistance to this kind of regimen is caused by impaired CPA activation 
[75]. The mechanisms of resistance formation to anti-angiogenic therapy are classified into 
four major groups: 1) evasive resistance, 2) vascular cooption, 3) reduced vascular 
dependence and 4) vascular remodeling [12]. In the present study the resistant tumor grows 
under conditions of hypoxia and restricted nutrients without the formation of additional 
tumor vessels [13] thus, the underlying mechanism leading to chemoresistance was assigned 
to the group of “reduced vascular dependence”. 
Previously to this work, a genome wide microarray was performed in a prostate cancer (PC3) 
xenograft model to investigate the molecular basis of in vivo resistance mechanisms to anti-
angiogenic CPA therapy. 
First the importance of appropriate in vivo controls was shown, as already the comparison of 
the gene expression profile of the in vivo passaged and standard PC3 tumors displayed a 
dramatic difference [14]. The gene expression profile of the standard, not in vivo passaged 
PC3 samples were clearly distinct from all other in vivo passaged tumor sublines (Figure 1-3). 
Moreover, gene expression of resistant tumors namely PC3 D3 and PC3 D4 clearly differed 
from the passaged not resistant PC3 A3 tumors. Within the group of resistant tumors an 
acute CPA treatment of the respective tumors for 24 hours only influenced gene expression 
marginally (Figure 1-3). All PC3 D3 samples from four mice clustered in one group, distinct 
from the PC3 D4 group. This indicates that resistant tumors of PC3 D3 and PC3 D4 share 
certain properties but originate from different cell clones. 
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The differentially expressed genes of untreated PC3 D3 and PC3 D4 versus PC3 A3 (in vivo 
passaged control) were regarded as more important and short term CPA effects were taken 
as lesser important. Approximately 50% of the differentially expressed genes in PC3 D3 and 
PC3 D4 versus PC3 A3 were shared by both resistant sub lines (Figure 1-4).  
 
For microarray validation the most differentially regulated genes dehydrogenase/reductase 
member 2 (DHRS2), PAS domain containing protein 1 (PASD1) and Neurotensin (NTS) as well 
as resistance related genes like special AT-rich sequence-binding protein-1 (SATB1) and bone 
morphogenetic protein receptor type I B (BMPR1B) were chosen (3.1.1). 
Dehydrogenase/reductase SDR family member 2 (DHRS2) is a less studied enzyme with the 
alternative name HEP27. It is described as a nuclear protein found in growth-arrested human 
hepatoblastoma cells. It is a member of the short-chain alcohol dehydrogenase family. 
Furthermore, its expression in fibroblasts is reported [76-78]. 
PAS domain containing protein 1 (PASD1) is also less studied. It is reported to be a 
leukaemia-associated antigen [79, 80]. 
Neurotensin (NTS) is an enzyme prominent in various kind of tissue. It was first isolated from 
extracts of the bovine hypothalamus [81]. Beside its function in endocrine cells of the small 
intestine, where it leads to secretion and smooth muscle contraction, it was also described 
to induce proliferation of colorectal cancer cells [82, 83]. 
Special AT-rich sequence-binding protein-1 (SATB1) is a transcription factor. It displays a key 
factor for integration of higher-order chromatin architecture with gene regulation [84-87]. 
Moreover, SATB1 expression is associated with a number of different kinds of cancer [88-
92]. Additionally, it has been reported to be involved in multidrug resistance of breast and 
colorectal cancer [93, 94] as well as in cisplatin resistance in hepatocellular carcinoma [64]. 
Bone morphogenetic protein receptor type I B (BMPR1B) is a member of the bone 
morphogenetic protein (BMP) receptor family, which members are transmembrane 
serine/threonine kinases. Their ligands are the BMPs (bone morphogenetic proteins) which 
are involved in endochondral bone formation and embryogenesis (reviewed by [95]). BMPs 
are also involved in cancer, exhibiting both oncogene and tumor suppressor gene functions 
[96]. 
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A qPCR analysis of these genes proofed the microarray results as valid. Furthermore, the 
expression of the named genes under cell culture conditions strongly differed between 
in vivo and in vitro. This finding agreed with the fact that resistant cell lines showed no 
resistance in vitro. 
 
To test the ability to induce resistance in vitro two genes were chosen: 1) SATB1, was 
strongly upregulated (5-fold) in resistant tumors in vivo but showed only a slight 
upregulation in PC3 D4 cells in vitro. 2) ANXA3, a protein previously found in a proteomic 
study to be more abundant in resistant PC3 clones on protein level [13], was upregulated 
in vivo but not in vitro. ANXA3 is a member of the Ca
2+
 binding-lipocortin family which are 
also known as annexins [97, 98]. 
The generation of SATB1 and ANXA3 overexpressing PC3 clones was performed by Mark 
Laible (DKFZ, Heidelberg). The induction of the target gene expression by doxycycline was 
feasible and led to the expression of the proper protein as shown by qPCR, western blot and 
immuno-fluorescence staining (3.1.2). Neither SATB1 nor ANXA3 overexpression led to 
resistance formation in vitro against the alkylating drug melphalan. However, SATB1 
overexpression induced resistance to cisplatin treatment. This finding confirms the work of 
Kuo et al. [64], who have described a role of SATB1 in cisplatin resistance in hepatocellular 
carcinoma by SATB1-mediated induction of survivin (Figure 4-1). An in vivo resistance of the 
transgenic PC3 clones was not tested for practical reasons and therefore cannot be 
excluded.  
 
Figure 4-1 Proposed model to explain the link between the viral protein HBx and the p38/MAPK pathway 
[64] 
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Due to the complex molecular evolution, leading to the ability to survive the restrictive 
conditions of anti-angiogenic therapy it is unlikely that a single main mechanism acts as a 
main factor for resistance acquisition. In the present study the expression of resistance 
related genes in vivo strongly differs from gene expression in vitro, indicating an involvement 
of microenvironmental factors leading to the observed in vivo resistance. Indeed, three 
pathways could be identified which potentially contribute to the described resistant 
phenotype (3.1.3): 1) axon guidance, 2) steroid biosynthesis and 3) complement and 
coagulation cascades. Prostate cancer cells are able to gain neuronal properties [99, 100], 
thus neuroendocrine-like differentiation might take place as a side effect of resistance 
formation. Steroid synthesis might be altered leading to hormone promoted increased 
proliferation. The most interesting functional group is “complement and coagulation 
cascades”. This group consists of six differentially expressed genes which are associated with 
the coagulation cascade. During anti-angiogenic treatment, blood vessels are destroyed and 
coagulation takes place. It was hypothesized that resistant tumor cells hamper the 
coagulation process in order to overcome the reduced oxygen and nutrient supply. This 
hypothesis is strengthened by the fact that it has been described for flavone acetic acid, also 
an anti-angiogenic drug, that the coagulation time in mice is strongly reduced [101]. Anti 
coagulation associated genes 1) PLAT (reviewed in [102]) and 2) ANXA3 [67] showed 
increased expression in resistant tumors, whereas expression of 3 members of the serine 
protease inhibitor family (SERPINs), which act potentially pro-coagulative [66] was decreased 
in resistant tumor tissue. Increased diffusion of oxygen and nutrients is facilitated by 
impaired thrombosis and fibrosis. 
In contrast to the finding that the expression of anti-coagulation genes is increased and of 
pro-coagulation genes is decreased, PROS a potential anti-coagulation factor [103] was 
downregulated and tissue factor (F3), the main mediator of the extrinsic pathway of blood 
coagulation [104, 105] was highly expressed in PC3 D4 tumor tissue. Interestingly, F3 shows 
an altered exon expression profile in PC3 D4 tumor samples. Comparing the expression level 
of PC3 D4 to PC3 A3, exons 3 to 6 are highly expressed in resistant PC3 D4 tumor tissue, 
whereas no differential expression of exon 1 and 2 can be seen. A version of F3, missing 
exon 1 and 2, has not yet been described, whereas an alternatively spliced variant of F3, 
missing exon 5, has been reported [106]. Exon 1 and 2 of F3 are coding for the first 70 amino 
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acids of the protein. In this area according to uniprot.org [107] a signal peptide and parts of a 
topological domain are located, leading to the hypothesis that the expression of an altered 
F3 protein might result in an impaired activation of blood coagulation by resistant tumor 
tissue or even in facilitating blood flow. 
 
Based on the microarray results, resistance to metronomic CPA therapy was sought to be 
induced by the application of anti-coagulation therapy to CPA treated PC3 A3 tumors in vivo 
(3.1.4). For anti-coagulation Warfarin was chosen. Warfarin is a 4-hydroxycoumarin, which 
inhibits the vitamin K-dependent step in clotting factor synthesis [108]. 
First Warfarin was administered through the drinking water as mice stopped drinking it was 
further administered i.p.. In this treatment regimen no enhanced resistance formation could 
be provoked by anti-coagulative therapy. The co-treatment using another anti-coagulative 
drug may be one opportunity to proof the involvement of coagulation in resistance 
formation. Another approach would be vice versa to inhibit resistance formation by 
induction of coagulation. 
In conclusion, resistance formation to metronomic CPA therapy can be seen as a molecular 
evolutionary process. Anti-coagulation properties of the cells (increased PLAT and ANXA3, 
increased exon deletion variant of F3, decreased SERPIND1, SERPINA1 and SERPINB7) could 
be part of a complex resistance mechanism, but the functional relevance remains to be 
confirmed by subsequent studies. 
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4.2 Myxobacterial compounds in cancer treatment 
Archazolid is a novel myxobacterial V-ATPase inhibitor. V-ATPases are conserved proton 
pumps involved in pH regulation of the cell. They recently came into focus as a novel target 
in cancer therapy because they are overexpressed in many tumor types. Their abundance at 
the plasma membrane in breast and pancreatic cancer cells was shown to correlate with an 
invasive phenotype [34, 109]. When inhibiting V-ATPase for therapeutic reasons, membrane 
bound V-ATPase was regarded as the primary target [110]. Their inhibition was proposed to 
elevate the extracellular pH, as tumors often have and an acidic microenvironment, which is 
correlated with an elevated invasive potential [36]. Moreover, an acidic microenvironment is 
related to an increased ability to express an elevated amount of growth and angiogenic 
factors [111, 112]. Moreover a raised intracellular pH is correlated with serum- and substrate 
independent growth and cell cycle progression [113-116]. 
However, the data presented here draw attention to another intriguing aspect of V-ATPase 
in cancer therapy: the inhibition of intracellular V-ATPase. In this study it could be shown 
that intracellular V-ATPases control the processing and secretion of lysosomal proteases, 
which are involved in tumor progression and metastasis [42-45, 57, 117]. 
 
Lysosomal proteases were found in the supernatants of archazolid treated urinary bladder 
carcinoma as well as of breast cancer cells. Further analysis revealed that predominantly the 
proforms of lysosomal proteases were secreted upon archazolid treatment. In particular 
V-ATPase inhibition by archazolid strongly induced the secretion of procathepsin B (3.2.2). 
Most importantly, the intracellular proteolytic activity of cathepsin B was strongly reduced 
after archazolid treatment, indicating an altered maturation process of cathepsin B (3.3.2). 
Furthermore, the impact of archazolid treatment on immune cells was evaluated. Archazolid 
induced reduction of intracellular cathepsin B was also detected in human macrophages 
(3.2.1). In monocytes no detectable amounts of cathepsin B were found and thus no 
archazolid action on cathepsin B maturation was present. But furthermore, the secretion 
profile of archazolid treated monocytes was analyzed and quantified (3.2.1). The secretion of 
thrombospondin (TSP1) was reduced in all three samples and thus displays a potential 
candidate for further evaluation. In one of the three samples interleukin 6 (IL-6) and 8 (IL-8) 
were less abundant. This is in accordance with unpublished results of the group of Prof. Dr. 
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Oliver Werz, Jena University. Using ELISA (Enzyme-linked immuno sorbent assay) they found 
that archazolid treated LPS-activated monocytes display a decreased secretion of IL-6 and IL-
8. Nevertheless, additional studies are necessary to evaluate a distinct action of archazolid 
on these cells. 
Focussing on archazolid action on cathepsin B maturation, it could be shown that the 
secretion of procathepsin B is a consequence of lysosome malfunction. Procathepsin B 
secretion was proven to be induced by other V-ATPase inhibitors bafilomycin and 
concanamycin as well as lysosomotropic agents chloroquine and NH4Cl (3.3.4, 3.3.5). 
Furthermore, RNAi experiments revealed that the archazolid effect on cathepsin B is a direct 
result from V-ATPase inhibition. Knockdown of the archazolid target domain V0c exhibited 
similar effects on cathepsin B maturation as archazolid treatment (3.3.3). 
Transport and activation of lysosomal proteases are carefully controlled processes [56]. 
Missorted, active proteases can lead to uncontrolled proteolysis and apoptosis. Many of 
those proteases are thus translated as inactive proforms. After glycosylation in the Golgi 
apparatus lysosomal proteases are bound to the mannose-6-phosphate-receptor (M6PR) 
(Figure 4-2 Schematic overview archazolid action on M6PR mediated trafficking). 
Subsequently, M6PR containing vesicles are fusing with prelysosomal compartments (PLC), 
followed by acidification of the vesicle by V-ATPase action. Receptor bound proteases can 
only be released if the pH is decreased, followed by a relocalization of M6PR to the trans-
Golgi network (TGN) [56, 57]. 
In contrast, if the pH cannot decrease in these PLC, e.g. caused by V-ATPase inhibition, the 
release of the cargo from M6PR is impaired and M6PR does not recycle to the TGN [72]. As a 
consequence newly glycosylated lysosomal proenzymes are accumulating and are thus 
transported out of the cell as there is no free M6PR they can be bound to (Figure 4-2). 
In accordance to the present study, also macrophages treated with V-ATPase inhibitor 
bafilomycin are reported to secreted elevated amounts of lysosomal proteases [118]. 
Likewise, the lysosomotropic, anti-malaria drug chloroquine was reported to strongly induce 
lysosomal enzyme secretion [119]. Moreover constitutive procathepsin D secretion by breast 
cancer cells (MCF-7) and colorectal cancer (CaCo-2) cells was found to be promoted by 
lysosome neutralizing reagent NH4Cl [120]. 
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Figure 4-2 Schematic overview archazolid action on M6PR mediated trafficking 
 
The in vitro results presented in the current study showed that archazolid blocks the 
maturation process of cathepsin B. Resulting in strongly decreased intracellular cathepsin B 
levels and a reduced cathepsin B activity. In cancer research lysosomal proteases like the 
cathepsins became more and more important as tumor markers [42-45]. Cathepsin B is 
upregulated in many types of cancer but its distinct role in tumor progression is not fully 
understood and controversially discussed. Nevertheless, cathepsin B genetic down 
regulation or inhibition by specific inhibitors has been shown to reduce invasive properties 
of cancer cells in vitro and in vivo [49, 51]. Earlier, a reduced activity of the pro-invasion 
protease matrix metalloproteinase 9 (MMP9) upon V-ATPase inhibition in pancreatic cancer 
was shown [109]. As it has been reported that inhibition of cathepsin B expression is linked 
to a decreased MMP9 activity in glioblastoma cells [121] the here presented results may be a 
link between these two publications. But most importantly, cathepsin B inhibition by the 
small molecule inhibitor CA-074 has been very recently shown to reduce bone metastasis of 
breast cancer cells in vivo [74]. The in vivo results of the present study showed that 
archazolid reduces the intracellular level of mature cathepsin B of tumor cells (3.4). In 
ER ER 
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particular, in a syngenic mouse model sub cutaneous tumors of mouse mammary gland 
tumor cells 4T1luc showed reduced cathepsin B protein amounts and had a reduced 
proteolytic cathepsin B activity. Furthermore, a functional correlation of reduced cathepsin B 
activity may be drawn to the fact that treated animals exhibited a reduced metastatic 
burden in the lungs, indicating that the reduction of cathepsin B by archazolid in tumors lead 
to a reduced metastatic potential of these cells. 
 
In summary, it could be shown that the V-ATPase inhibitor archazolid reduces the 
intracellular activity of pro-invasion cathepsin B. Furthermore the present study provides 
additional information how inhibition of the V-ATPase can lead to the reduction of the 
invasive potential of cancer cells by blockage of mannose-6-phosphate mediated maturation 
of lysosomal proteases. Moreover, in a pharmaceutical point of view, archazolid displays 
various advantages compared to an anti-metastatic therapy using specific cathepsin B 
inhibitors which are no V-ATPase inhibitors: Archazolid reduces 1) the invasive potential by 
inhibition of membrane bound V-ATPase 2) the migratory potential [29] and 3) the activity of 
pro-metastatic proteases. Furthermore it has been shown that archazolid specifically induces 
apoptosis in cancer cells [30]. 
 
Taken together archazolid can be proposed as a promising anti-metastatic drug. 
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5 Summary 
In the present study the mechanisms leading to acquired chemoresistance, as well as new 
treatment strategies implying the prevention evading of tumor cells were addressed. 
Resistance formation is one of the major hurdles in cancer therapy. Metronomic anti-
angiogenic treatment of xenografted prostate cancer tumors in mice with cyclophosphamide 
(CPA) results in the appearance of resistant tumors. To investigate the complex molecular 
changes occurring during resistance formation, a comprehensive gene expression analysis of 
the resistant tumors in vivo was performed. A multitude of differentially expressed genes, 
e.g. PAS domain containing protein 1 (PASD1), annexin A3 (ANXA3), neurotensin (NTS) or 
plasminogen activator tissue (PLAT), were observed, when comparing resistant to in vivo 
passaged tumor samples. Moreover, tumor cells from in vivo and in vitro conditions showed 
a significant difference in target gene expression. For clarification of the mechanisms leading 
to the survival of tumor cells during maintained anti-angiogenic CPA therapy the 
differentially expressed genes were assigned to functional pathways like: axon guidance, 
steroid biosynthesis and complement and coagulation cascades. As blood flow might play a 
crucial role during maintained anti-angiogenic therapy, further analysis was focused on the 
genes grouped in complement and coagulation cascades. Upregulation of anti-coagulatory 
ANXA3 and PLAT and downregulation of SERPIN A1 and other SERPIN-family members was 
shown by qPCR analysis. In contrast coagulation factor F3 was upregulated, accompanied by 
the expression of an altered gene product. Taken together, a potential role of anti-
coagulation as a resistance mechanism for anti-angiogenic CPA therapy could be described. 
Furthermore, the role of archazolid, a novel myxobacterial V-ATPase inhibitor in cancer 
treatment and in particular its action on the secreted cellular proteome was evaluated. As 
extracellular protein secretion may have an impact on invasive properties of tumor cells, the 
changes of the secretome profile of highly migratory urinary bladder carcinoma cells upon 
archazolid treatment were analyzed. An induced secretion of prometastatic lysosomal 
proteins such as the cathepsin family was observed. Interestingly, intracellular cathepsin B 
activity however strongly decreases and mature cathepsin B protein diminishes. It could be 
shown that archazolid inhibits the mannose-6-phosphate receptor mediated trafficking of 
procathepsin B from the trans-Golgi network to prelysosomal compartments, leading to an 
impaired cathepsin B maturation process. This results in an unnatural secretion of the 
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inactive proenzyme and a dramatic decrease in intracellular cathepsin B activity. 
Importantly, also in vivo an archazolid induced reduction of cathepsin B activity was proven 
and archazolid treatment resulted in a reduced formation of distant metastases in the lungs. 
In summary these results indicate that archazolid in addition to its known anti-migratory 
properties might exert an anti-metastatic effect by reducing the activity of pro metastatic 
proteases like cathepsin B. 
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6 Abbreviations 
DNA  deoxyribonucleic acid 
LC-MS/MS liqud chromatography tandem mass spectormetry 
µM micro molar (10-6) 
4-HOO-CPA 4-hydroxy cyclophosphamide 
APS ammonium persulfate 
arch archazolid 
ATP adenosin-5`-triphosphat 
bafA bafilomycin A1 
BALB/c mus musculus laboratory inbred strain 
BCA bicinchoninic acid 
bref brefeldin 
cDNA complementary DNA 
concA concanamycin A 
CP chlorpromazine 
CPA cyclophosphamide 
CQ chloroquine 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco`s Modified Essential Medium 
DMSO dimethyl sulfoxid 
dox doxycycline 
DTT dithiothreitol 
e.g. exempli gratia (for example) 
EDTA ethylenediamine tetraacetic acid 
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FCS fetal calf serum 
i.p. intraperitoneal(ly) 
i.v. intravenous(ly) 
kDa kilo dalton 
LSM laser scanning microscope 
mM milli molar (10
-3
) 
mRNA messenger ribobucleic acid 
nM nano molar (10
-9
) 
PBS phosphate buffered saline 
PVDF polyvinylidene fluoride 
qPCR quantitative polymerase chain reaction  
RMA robust multichip analysis 
RNA ribonucleic acid 
RT room temperature 
s.c. sub cutaneous(ly) 
S.E.M. standard error of the mean 
SCID severe combined immuno deficiency 
SDS sodium dodecyl sulfate -polyacrylamide gel electrophoresis 
SDS-PAGE sodium dodecyl sulfate 
siRNA small interfering ribonucleic acid 
TEMED Tetramethylene ethane diamine 
TGN trans-Golgi network 
Tris trishydroxymethylaminomethane 
tunm tunicamycin 
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10 Appendix 
Table 10-1 List of identified proteins in supernatants of archazolid treated T-24 cells 
Numbers on the right indicate the quantity of different identified peptides in each replicate (1-5). 
# Identified Proteins (375) Accession r1 r2 r3 r4 r5 
1 Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 FINC_HUMAN 63 55 51 70 72 
2 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 
K2C1_HUMAN 13 21 25 16 16 
3 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 ENOA_HUMAN 18 18 19 21 25 
4 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP 
PE=1 SV=1 
LG3BP_HUMAN 16 16 18 20 17 
5 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
K1C10_HUMAN 14 20 23 12 14 
6 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 5 5 7 8 7 
7 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 ACTB_HUMAN 13 14 15 18 19 
8 Pentraxin-related protein PTX3 OS=Homo sapiens GN=PTX3 
PE=1 SV=3 
PTX3_HUMAN 14 10 9 13 10 
9 EGF-containing fibulin-like extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 PE=1 SV=2 
FBLN3_HUMAN 13 13 10 14 12 
10 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 
SV=3 
TPIS_HUMAN 16 14 14 16 19 
11 Collagen alpha-1(VI) chain OS=Homo sapiens GN=COL6A1 PE=1 
SV=3 
CO6A1_HUMAN 17 14 13 21 24 
12 Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM 
PE=1 SV=4 
KPYM_HUMAN 11 12 8 20 26 
13 Insulin-like growth factor-binding protein 7 OS=Homo sapiens 
GN=IGFBP7 PE=1 SV=1 
IBP7_HUMAN 14 13 14 9 6 
14 Heat shock cognate 71 kDa protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 
HSP7C_HUMAN 16 10 11 22 23 
15 Laminin subunit alpha-5 OS=Homo sapiens GN=LAMA5 PE=1 
SV=8 
LAMA5_HUMAN 35 28 20 39 23 
16 Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 ACTN4_HUMAN 5 12 23 31 33 
17 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 FLNA_HUMAN 15 7 17 30 37 
18 Sulfhydryl oxidase 1 OS=Homo sapiens GN=QSOX1 PE=1 SV=3 QSOX1_HUMAN 16 9 15 19 16 
19 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 
SV=3 
K1C9_HUMAN 10 15 16 5 7 
20 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 
K22E_HUMAN 4 18 16 6 8 
21 Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 
SV=3 
PGK1_HUMAN 12 14 12 15 19 
22 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 PROF1_HUMAN 13 4 7 11 13 
23 Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA 
PE=1 SV=2 
PPIA_HUMAN 12 3 6 13 15 
24 Calsyntenin-1 OS=Homo sapiens GN=CLSTN1 PE=1 SV=1 CSTN1_HUMAN 15 7 6 17 20 
25 Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens 
GN=RPS27A PE=1 SV=2 
RS27A_HUMAN 3 4 4 7 8 
26 Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA 
PE=1 SV=2 
ALDOA_HUMAN 15 16 12 14 12 
27 Heat shock protein HSP 90-alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 SV=5 
HS90A_HUMAN 0 9 11 21 23 
28 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 
G3P_HUMAN 7 5 6 8 13 
29 L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA 
PE=1 SV=2 
LDHA_HUMAN 4 5 5 13 14 
30 Metalloproteinase inhibitor 1 OS=Homo sapiens GN=TIMP1 PE=1 
SV=1 
TIMP1_HUMAN 4 4 6 8 5 
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31 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 
SV=1 
1433Z_HUMAN 14 7 8 14 16 
32 Laminin subunit gamma-2 OS=Homo sapiens GN=LAMC2 PE=1 
SV=2 
LAMC2_HUMAN 12 0 0 24 15 
33 Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 MOES_HUMAN 1 7 5 21 22 
34 Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 B2MG_HUMAN 6 3 5 5 4 
35 Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 VINC_HUMAN 6 8 15 13 22 
36 Filamin-B OS=Homo sapiens GN=FLNB PE=1 SV=2 FLNB_HUMAN 2 8 14 21 30 
37 Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 COF1_HUMAN 7 4 4 7 9 
38 Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 
SV=2 
PGAM1_HUMAN 9 4 11 9 8 
39 Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 EF2_HUMAN 1 2 2 15 23 
40 Insulin-like growth factor-binding protein 4 OS=Homo sapiens 
GN=IGFBP4 PE=1 SV=2 
IBP4_HUMAN 5 3 6 9 4 
41 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 
SV=1 
TBA1B_HUMAN 7 3 4 10 12 
42 Laminin subunit gamma-1 OS=Homo sapiens GN=LAMC1 PE=1 
SV=3 
LAMC1_HUMAN 12 12 8 19 14 
43 Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 TKT_HUMAN 3 6 4 8 18 
44 Follistatin-related protein 1 OS=Homo sapiens GN=FSTL1 PE=1 
SV=1 
FSTL1_HUMAN 9 9 5 11 8 
45 Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 FETUA_HUMAN 3 3 2 3 3 
46 Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 ACTN1_HUMAN 3 5 7 13 14 
47 Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 
SV=1 
EF1A1_HUMAN 6 3 2 6 10 
48 Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 ANXA2_HUMAN 3 5 6 15 11 
49 Plasminogen activator inhibitor 1 OS=Homo sapiens 
GN=SERPINE1 PE=1 SV=1 
PAI1_HUMAN 5 5 4 7 6 
50 Laminin subunit beta-1 OS=Homo sapiens GN=LAMB1 PE=1 SV=2 LAMB1_HUMAN 11 4 2 14 14 
51 Insulin-like growth factor-binding protein 6 OS=Homo sapiens 
GN=IGFBP6 PE=1 SV=1 
IBP6_HUMAN 4 5 6 7 4 
52 Tubulointerstitial nephritis antigen-like OS=Homo sapiens 
GN=TINAGL1 PE=1 SV=1 
TINAL_HUMAN 10 6 7 7 7 
53 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 TRFL_HUMAN 4 3 2 3 2 
54 Heat shock protein HSP 90-beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 
HS90B_HUMAN 0 3 4 13 13 
55 Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A 
PE=1 SV=5 
HSP71_HUMAN 3 2 0 4 12 
56 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 4 3 4 3 3 
57 Fascin OS=Homo sapiens GN=FSCN1 PE=1 SV=3 FSCN1_HUMAN 4 5 4 8 13 
58 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 CLUS_HUMAN 7 3 4 10 8 
59 Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens 
GN=UBA1 PE=1 SV=3 
UBA1_HUMAN 1 2 4 4 18 
60 Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 GELS_HUMAN 7 2 3 12 8 
61 Proactivator polypeptide OS=Homo sapiens GN=PSAP PE=1 SV=2 SAP_HUMAN 11 2 0 5 5 
62 Serglycin OS=Homo sapiens GN=SRGN PE=1 SV=3 SRGN_HUMAN 3 3 3 6 5 
63 Transitional endoplasmic reticulum ATPase OS=Homo sapiens 
GN=VCP PE=1 SV=4 
TERA_HUMAN 0 6 8 6 14 
64 SPARC OS=Homo sapiens GN=SPARC PE=1 SV=1 SPRC_HUMAN 5 4 2 6 6 
65 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 
SV=3 
1433B_HUMAN 6 2 3 6 9 
66 Tissue-type plasminogen activator OS=Homo sapiens GN=PLAT 
PE=1 SV=1 
TPA_HUMAN 5 1 0 9 10 
  
Appendix 
94 
 
67 Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 PRDX1_HUMAN 7 2 4 7 5 
68 Lysyl oxidase homolog 2 OS=Homo sapiens GN=LOXL2 PE=1 
SV=1 
LOXL2_HUMAN 7 1 0 10 5 
69 Connective tissue growth factor OS=Homo sapiens GN=CTGF 
PE=1 SV=2 
CTGF_HUMAN 9 3 3 6 4 
70 L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB 
PE=1 SV=2 
LDHB_HUMAN 2 5 3 9 9 
71 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 
SV=5 
CO1A1_HUMAN 0 2 2 0 1 
72 Cadherin-2 OS=Homo sapiens GN=CDH2 PE=1 SV=4 CADH2_HUMAN 10 3 4 6 6 
73 Plectin OS=Homo sapiens GN=PLEC PE=1 SV=3 PLEC_HUMAN 0 3 5 15 5 
74 Adenosylhomocysteinase OS=Homo sapiens GN=AHCY PE=1 
SV=4 
SAHH_HUMAN 4 5 7 7 11 
75 Amyloid beta A4 protein OS=Homo sapiens GN=APP PE=1 SV=3 A4_HUMAN 2 3 1 12 4 
76 Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 
SV=4 
G6PI_HUMAN 4 5 4 3 9 
77 Gamma-glutamyl hydrolase OS=Homo sapiens GN=GGH PE=1 
SV=2 
GGH_HUMAN 5 2 3 4 3 
78 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 TBB5_HUMAN 2 0 5 9 11 
79 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 LEG1_HUMAN 6 0 4 5 6 
80 Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 
SV=2 
GSTP1_HUMAN 5 5 4 6 6 
81 CD166 antigen OS=Homo sapiens GN=ALCAM PE=1 SV=2 CD166_HUMAN 7 6 5 4 4 
82 Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4 FBLN1_HUMAN 3 3 4 7 7 
83 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 
PE=1 SV=2 
GRP78_HUMAN 0 4 8 13 4 
84 Nidogen-1 OS=Homo sapiens GN=NID1 PE=1 SV=3 NID1_HUMAN 2 1 0 14 12 
85 Chloride intracellular channel protein 1 OS=Homo sapiens 
GN=CLIC1 PE=1 SV=4 
CLIC1_HUMAN 1 2 5 6 10 
86 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 TSP1_HUMAN 0 1 0 11 10 
87 Latent-transforming growth factor beta-binding protein 2 
OS=Homo sapiens GN=LTBP2 PE=1 SV=3 
LTBP2_HUMAN 8 2 0 6 4 
88 Cystatin-C OS=Homo sapiens GN=CST3 PE=1 SV=1 CYTC_HUMAN 3 0 1 3 3 
89 Nucleoside diphosphate kinase B OS=Homo sapiens GN=NME2 
PE=1 SV=1 
NDKB_HUMAN 5 0 0 7 5 
90 Heat shock 70 kDa protein 4 OS=Homo sapiens GN=HSPA4 PE=1 
SV=4 
HSP74_HUMAN 3 1 2 7 7 
91 Dickkopf-related protein 3 OS=Homo sapiens GN=DKK3 PE=1 
SV=2 
DKK3_HUMAN 2 3 2 5 7 
92 Metalloproteinase inhibitor 2 OS=Homo sapiens GN=TIMP2 PE=1 
SV=2 
TIMP2_HUMAN 3 2 0 4 3 
93 Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 
SV=3 
PDIA1_HUMAN 0 3 2 8 7 
94 Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB 
PE=1 SV=2 
PPIB_HUMAN 4 4 3 5 3 
95 Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 EZRI_HUMAN 0 1 0 7 9 
96 Carboxypeptidase A4 OS=Homo sapiens GN=CPA4 PE=1 SV=2 CBPA4_HUMAN 6 5 3 6 3 
97 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1433E_HUMAN 2 4 4 5 5 
98 Tyrosine-protein kinase receptor UFO OS=Homo sapiens GN=AXL 
PE=1 SV=3 
UFO_HUMAN 4 2 3 5 4 
99 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 H4_HUMAN 2 0 3 4 4 
100 Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 PRDX2_HUMAN 2 0 0 4 7 
101 Keratin, type I cytoskeletal 18 OS=Homo sapiens GN=KRT18 PE=1 
SV=2 
K1C18_HUMAN 2 0 2 6 5 
102 Collagen alpha-2(VI) chain OS=Homo sapiens GN=COL6A2 PE=1 CO6A2_HUMAN 3 1 1 9 6 
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SV=4 
103 Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 
SV=3 
EF1G_HUMAN 5 3 0 5 7 
104 Fatty acid-binding protein, epidermal OS=Homo sapiens 
GN=FABP5 PE=1 SV=3 
FABP5_HUMAN 5 0 0 4 6 
105 Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 
SV=7 
K2C8_HUMAN 2 0 1 9 7 
106 Histone H2B type 1-C/E/F/G/I OS=Homo sapiens GN=HIST1H2BC 
PE=1 SV=4 
H2B1C_HUMAN 2 1 0 6 2 
107 Alpha-fetoprotein OS=Homo sapiens GN=AFP PE=1 SV=1 FETA_HUMAN 2 2 2 2 0 
108 CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 CD44_HUMAN 2 3 1 3 5 
109 Collagen alpha-2(V) chain OS=Homo sapiens GN=COL5A2 PE=1 
SV=3 
CO5A2_HUMAN 3 4 5 2 0 
110 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 
SV=7 
CO1A2_HUMAN 0 2 2 3 3 
111 Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 PARK7_HUMAN 5 0 1 6 6 
112 Fibrillin-1 OS=Homo sapiens GN=FBN1 PE=1 SV=3 FBN1_HUMAN 2 0 0 13 5 
113 Syndecan-4 OS=Homo sapiens GN=SDC4 PE=1 SV=2 SDC4_HUMAN 5 3 2 2 3 
114 Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 COTL1_HUMAN 3 0 2 1 5 
115 Protein CYR61 OS=Homo sapiens GN=CYR61 PE=1 SV=1 CYR61_HUMAN 4 4 2 1 3 
116 Rab GDP dissociation inhibitor beta OS=Homo sapiens GN=GDI2 
PE=1 SV=2 
GDIB_HUMAN 1 2 3 3 8 
117 Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 FAS_HUMAN 1 0 0 2 18 
118 Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 
PE=1 SV=1 
IF4A1_HUMAN 0 0 0 5 11 
119 Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 MYH9_HUMAN 0 1 5 3 7 
120 Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 TALDO_HUMAN 1 3 3 6 2 
121 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 THIO_HUMAN 3 0 1 4 5 
122 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 CLH1_HUMAN 0 1 3 3 7 
123 MAM domain-containing protein 2 OS=Homo sapiens 
GN=MAMDC2 PE=2 SV=3 
MAMC2_HUMAN 4 0 0 6 3 
124 Cathepsin Z OS=Homo sapiens GN=CTSZ PE=1 SV=1 CATZ_HUMAN 3 2 3 4 2 
125 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA 
PE=1 SV=1 
PCNA_HUMAN 4 0 1 8 2 
126 Phosphatidylethanolamine-binding protein 1 OS=Homo sapiens 
GN=PEBP1 PE=1 SV=3 
PEBP1_HUMAN 2 2 4 3 5 
127 Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo 
sapiens GN=HNRNPA2B1 PE=1 SV=2 
ROA2_HUMAN 2 2 1 6 3 
128 Metallothionein-1G OS=Homo sapiens GN=MT1G PE=1 SV=2 MT1G_HUMAN 1 1 2 1 3 
129 Plastin-3 OS=Homo sapiens GN=PLS3 PE=1 SV=4 PLST_HUMAN 0 0 0 2 16 
130 Dickkopf-related protein 1 OS=Homo sapiens GN=DKK1 PE=1 
SV=1 
DKK1_HUMAN 1 3 1 5 2 
131 Macrophage migration inhibitory factor OS=Homo sapiens 
GN=MIF PE=1 SV=4 
MIF_HUMAN 2 1 1 2 2 
132 Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3 TAGL2_HUMAN 3 0 0 5 9 
133 Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 
SV=2 
HBA_HUMAN 3 0 0 2 3 
134 Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 
PE=1 SV=4 
PDIA3_HUMAN 0 3 2 8 2 
135 Testican-1 OS=Homo sapiens GN=SPOCK1 PE=1 SV=1 TICN1_HUMAN 2 0 0 5 6 
136 Neural cell adhesion molecule L1 OS=Homo sapiens GN=L1CAM 
PE=1 SV=2 
L1CAM_HUMAN 2 4 3 1 2 
137 Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 XPO2_HUMAN 0 0 0 1 6 
138 Semaphorin-4B OS=Homo sapiens GN=SEMA4B PE=1 SV=3 SEM4B_HUMAN 3 2 1 4 1 
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139 Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 
SV=2 
IMB1_HUMAN 0 0 0 4 10 
140 GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN 
PE=1 SV=3 
RAN_HUMAN 1 1 3 1 4 
141 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A 
PE=1 SV=3 
K2C6A_HUMAN 0 4 2 1 1 
142 Glycogen phosphorylase, brain form OS=Homo sapiens 
GN=PYGB PE=1 SV=5 
PYGB_HUMAN 0 0 1 3 10 
143 Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 CATD_HUMAN 6 5 0 0 0 
144 WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 
PE=1 SV=4 
WDR1_HUMAN 3 1 0 1 5 
145 Amyloid-like protein 2 OS=Homo sapiens GN=APLP2 PE=1 SV=2 APLP2_HUMAN 0 0 1 4 3 
146 Puromycin-sensitive aminopeptidase OS=Homo sapiens 
GN=NPEPPS PE=1 SV=2 
PSA_HUMAN 0 0 2 3 9 
147 Histone H2A type 1-D OS=Homo sapiens GN=HIST1H2AD PE=1 
SV=2 
H2A1D_HUMAN 1 2 3 2 2 
148 Histone H3.1t OS=Homo sapiens GN=HIST3H3 PE=1 SV=3 H31T_HUMAN 1 0 0 3 2 
149 Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB 
PE=1 SV=3 
GANAB_HUMAN 3 1 1 1 0 
150 Exostosin-1 OS=Homo sapiens GN=EXT1 PE=1 SV=2 EXT1_HUMAN 2 2 2 2 2 
151 Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 ATRN_HUMAN 4 2 3 2 1 
152 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens 
GN=ITIH2 PE=1 SV=2 
ITIH2_HUMAN 3 2 3 1 0 
153 Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 1 0 2 2 0 
154 40S ribosomal protein S12 OS=Homo sapiens GN=RPS12 PE=1 
SV=3 
RS12_HUMAN 2 0 0 3 4 
155 Dystroglycan OS=Homo sapiens GN=DAG1 PE=1 SV=2 DAG1_HUMAN 2 1 3 3 1 
156 60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 
SV=1 
RL12_HUMAN 2 1 1 3 3 
157 Annexin A3 OS=Homo sapiens GN=ANXA3 PE=1 SV=3 ANXA3_HUMAN 0 3 7 0 0 
158 Malate dehydrogenase, cytoplasmic OS=Homo sapiens 
GN=MDH1 PE=1 SV=4 
MDHC_HUMAN 3 1 0 3 3 
159 Exostosin-2 OS=Homo sapiens GN=EXT2 PE=1 SV=1 EXT2_HUMAN 0 1 1 5 3 
160 Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3 CATB_HUMAN 3 2 0 1 0 
161 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 OS=Homo 
sapiens GN=PLOD1 PE=1 SV=2 
PLOD1_HUMAN 0 1 1 5 4 
162 Rho GDP-dissociation inhibitor 1 OS=Homo sapiens 
GN=ARHGDIA PE=1 SV=3 
GDIR1_HUMAN 1 0 0 3 3 
163 Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens 
GN=HNRNPA1 PE=1 SV=5 
ROA1_HUMAN 1 0 0 5 3 
164 Aspartate aminotransferase, mitochondrial OS=Homo sapiens 
GN=GOT2 PE=1 SV=3 
AATM_HUMAN 1 4 4 0 0 
165 Agrin OS=Homo sapiens GN=AGRN PE=1 SV=4 AGRIN_HUMAN 6 0 0 0 0 
166 Fructose-bisphosphate aldolase C OS=Homo sapiens GN=ALDOC 
PE=1 SV=2 
ALDOC_HUMAN 2 1 2 2 2 
167 Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 
PE=1 SV=1 
NPC2_HUMAN 3 1 1 1 2 
168 Malate dehydrogenase, mitochondrial OS=Homo sapiens 
GN=MDH2 PE=1 SV=3 
MDHM_HUMAN 2 6 4 1 0 
169 Non-histone chromosomal protein HMG-17 OS=Homo sapiens 
GN=HMGN2 PE=1 SV=3 
HMGN2_HUMAN 1 0 1 1 2 
170 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 2 1 0 2 0 
171 Laminin subunit beta-3 OS=Homo sapiens GN=LAMB3 PE=1 SV=1 LAMB3_HUMAN 3 0 0 3 4 
172 Actin-related protein 2/3 complex subunit 4 OS=Homo sapiens 
GN=ARPC4 PE=1 SV=3 
ARPC4_HUMAN 0 0 1 5 4 
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173 Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1 LMNA_HUMAN 0 0 0 8 1 
174 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 HORN_HUMAN 0 3 3 0 0 
175 Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens 
GN=FKBP1A PE=1 SV=2 
FKB1A_HUMAN 2 1 1 1 2 
176 Thioredoxin domain-containing protein 17 OS=Homo sapiens 
GN=TXNDC17 PE=1 SV=1 
TXD17_HUMAN 2 0 2 2 4 
177 Protein-glutamine gamma-glutamyltransferase 2 OS=Homo 
sapiens GN=TGM2 PE=1 SV=2 
TGM2_HUMAN 0 0 2 5 3 
178 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3 
K2C5_HUMAN 0 3 2 0 0 
179 Stathmin OS=Homo sapiens GN=STMN1 PE=1 SV=3 STMN1_HUMAN 2 0 0 2 4 
180 Granulins OS=Homo sapiens GN=GRN PE=1 SV=2 GRN_HUMAN 5 1 0 1 1 
181 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 RINI_HUMAN 0 1 1 3 3 
182 4F2 cell-surface antigen heavy chain OS=Homo sapiens 
GN=SLC3A2 PE=1 SV=3 
4F2_HUMAN 6 0 1 1 0 
183 Importin-5 OS=Homo sapiens GN=IPO5 PE=1 SV=4 IPO5_HUMAN 0 0 2 3 2 
184 Proteasome subunit alpha type-6 OS=Homo sapiens GN=PSMA6 
PE=1 SV=1 
PSA6_HUMAN 2 1 1 4 3 
185 Proteasome subunit alpha type-7 OS=Homo sapiens GN=PSMA7 
PE=1 SV=1 
PSA7_HUMAN 2 0 2 3 2 
186 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 OS=Homo 
sapiens GN=PLOD2 PE=1 SV=2 
PLOD2_HUMAN 3 1 0 3 2 
187 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 ENPL_HUMAN 0 1 2 5 0 
188 Stress-induced-phosphoprotein 1 OS=Homo sapiens GN=STIP1 
PE=1 SV=1 
STIP1_HUMAN 1 0 0 1 5 
189 Ubiquitin-like protein ISG15 OS=Homo sapiens GN=ISG15 PE=1 
SV=5 
ISG15_HUMAN 1 0 0 1 3 
190 Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2 BTD_HUMAN 1 3 1 1 2 
191 Lactoylglutathione lyase OS=Homo sapiens GN=GLO1 PE=1 SV=4 LGUL_HUMAN 1 0 1 1 3 
192 Inactive tyrosine-protein kinase 7 OS=Homo sapiens GN=PTK7 
PE=1 SV=2 
PTK7_HUMAN 4 2 1 1 0 
193 Ras GTPase-activating-like protein IQGAP1 OS=Homo sapiens 
GN=IQGAP1 PE=1 SV=1 
IQGA1_HUMAN 1 1 0 1 4 
194 Eukaryotic translation initiation factor 5A-1 OS=Homo sapiens 
GN=EIF5A PE=1 SV=2 
IF5A1_HUMAN 1 0 0 2 4 
195 Eukaryotic translation initiation factor 6 OS=Homo sapiens 
GN=EIF6 PE=1 SV=1 
IF6_HUMAN 2 0 0 4 2 
196 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 
K1C14_HUMAN 0 3 2 1 0 
197 Translationally-controlled tumor protein OS=Homo sapiens 
GN=TPT1 PE=1 SV=1 
TCTP_HUMAN 2 0 0 1 0 
198 Poliovirus receptor OS=Homo sapiens GN=PVR PE=1 SV=2 PVR_HUMAN 1 1 2 2 2 
199 Proteasome subunit alpha type-2 OS=Homo sapiens GN=PSMA2 
PE=1 SV=2 
PSA2_HUMAN 2 0 0 1 1 
200 Deoxyuridine 5'-triphosphate nucleotidohydrolase, 
mitochondrial OS=Homo sapiens GN=DUT PE=1 SV=4 
DUT_HUMAN 2 0 1 2 3 
201 SH3 domain-binding glutamic acid-rich-like protein 3 OS=Homo 
sapiens GN=SH3BGRL3 PE=1 SV=1 
SH3L3_HUMAN 2 0 1 1 3 
202 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 
SV=2 
RL10A_HUMAN 1 0 0 5 2 
203 Phosphoribosylformylglycinamidine synthase OS=Homo sapiens 
GN=PFAS PE=1 SV=4 
PUR4_HUMAN 0 0 0 0 7 
204 Semaphorin-7A OS=Homo sapiens GN=SEMA7A PE=1 SV=1 SEM7A_HUMAN 3 1 1 2 1 
205 Glucosidase 2 subunit beta OS=Homo sapiens GN=PRKCSH PE=1 
SV=2 
GLU2B_HUMAN 1 2 1 1 2 
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206 Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 
PE=1 SV=1 
PDIA6_HUMAN 0 2 2 3 1 
207 Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 PRDX6_HUMAN 3 0 0 2 2 
208 Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 
SV=2 
SODC_HUMAN 0 1 2 0 1 
209 Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo 
sapiens GN=SERBP1 PE=1 SV=2 
PAIRB_HUMAN 2 0 0 1 1 
210 Metastasis-suppressor KiSS-1 OS=Homo sapiens GN=KISS1 PE=1 
SV=4 
KISS1_HUMAN 0 0 0 3 2 
211 Signal-regulatory protein beta-1 OS=Homo sapiens GN=SIRPB1 
PE=1 SV=5 
SIRB1_HUMAN 0 0 2 0 0 
212 Beta-hexosaminidase subunit alpha OS=Homo sapiens GN=HEXA 
PE=1 SV=2 
HEXA_HUMAN 5 2 0 0 0 
213 Xaa-Pro dipeptidase OS=Homo sapiens GN=PEPD PE=1 SV=3 PEPD_HUMAN 3 2 2 1 2 
214 Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens 
GN=ITIH4 PE=1 SV=4 
ITIH4_HUMAN 1 1 2 1 0 
215 Glutathione synthetase OS=Homo sapiens GN=GSS PE=1 SV=1 GSHB_HUMAN 2 0 0 1 2 
216 Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 PE=1 
SV=2 
COCA1_HUMAN 3 3 1 0 0 
217 Lysosomal Pro-X carboxypeptidase OS=Homo sapiens GN=PRCP 
PE=1 SV=1 
PCP_HUMAN 4 0 0 0 1 
218 10 kDa heat shock protein, mitochondrial OS=Homo sapiens 
GN=HSPE1 PE=1 SV=2 
CH10_HUMAN 2 0 0 3 2 
219 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 1433G_HUMAN 3 0 0 3 1 
220 Proteasome subunit alpha type-4 OS=Homo sapiens GN=PSMA4 
PE=1 SV=1 
PSA4_HUMAN 1 1 1 3 1 
221 Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 S10A6_HUMAN 0 1 0 2 1 
222 Aspartate aminotransferase, cytoplasmic OS=Homo sapiens 
GN=GOT1 PE=1 SV=3 
AATC_HUMAN 0 3 3 1 1 
223 Soluble calcium-activated nucleotidase 1 OS=Homo sapiens 
GN=CANT1 PE=1 SV=1 
CANT1_HUMAN 2 1 1 4 0 
224 NKG2D ligand 2 OS=Homo sapiens GN=ULBP2 PE=1 SV=1 N2DL2_HUMAN 2 0 1 1 1 
225 Ubiquitin-conjugating enzyme E2 N OS=Homo sapiens 
GN=UBE2N PE=1 SV=1 
UBE2N_HUMAN 2 0 0 3 3 
226 Tubulin-specific chaperone A OS=Homo sapiens GN=TBCA PE=1 
SV=3 
TBCA_HUMAN 1 0 0 3 3 
227 Proteasome subunit beta type-6 OS=Homo sapiens GN=PSMB6 
PE=1 SV=4 
PSB6_HUMAN 2 0 0 2 1 
228 Cellular nucleic acid-binding protein OS=Homo sapiens 
GN=CNBP PE=1 SV=1 
CNBP_HUMAN 1 0 0 1 4 
229 Threonine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=TARS 
PE=1 SV=3 
SYTC_HUMAN 0 0 1 0 6 
230 Proteasome subunit alpha type-1 OS=Homo sapiens GN=PSMA1 
PE=1 SV=1 
PSA1_HUMAN 0 0 2 4 0 
231 6-phosphogluconolactonase OS=Homo sapiens GN=PGLS PE=1 
SV=2 
6PGL_HUMAN 2 0 1 1 1 
232 Beta-enolase OS=Homo sapiens GN=ENO3 PE=1 SV=5 ENOB_HUMAN 1 0 1 1 2 
233 Stanniocalcin-2 OS=Homo sapiens GN=STC2 PE=1 SV=1 STC2_HUMAN 0 1 0 4 1 
234 Elongation factor 1-delta OS=Homo sapiens GN=EEF1D PE=1 
SV=5 
EF1D_HUMAN 0 0 0 3 0 
235 Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 
PE=1 SV=2 
THBG_HUMAN 0 0 0 2 2 
236 Nucleobindin-1 OS=Homo sapiens GN=NUCB1 PE=1 SV=4 NUCB1_HUMAN 0 0 0 0 2 
237 Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 
PE=1 SV=3 
PSA5_HUMAN 3 0 0 2 1 
238 Ubiquitin-conjugating enzyme E2 variant 1 OS=Homo sapiens 
GN=UBE2V1 PE=1 SV=2 
UB2V1_HUMAN 0 0 0 0 2 
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239 ATP synthase subunit beta, mitochondrial OS=Homo sapiens 
GN=ATP5B PE=1 SV=3 
ATPB_HUMAN 0 2 4 0 0 
240 Cysteine-rich protein 1 OS=Homo sapiens GN=CRIP1 PE=1 SV=3 CRIP1_HUMAN 0 0 0 1 2 
241 Dipeptidyl peptidase 3 OS=Homo sapiens GN=DPP3 PE=1 SV=2 DPP3_HUMAN 0 1 1 1 2 
242 Pigment epithelium-derived factor OS=Homo sapiens 
GN=SERPINF1 PE=1 SV=4 
PEDF_HUMAN 1 3 1 2 0 
243 Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 TLN1_HUMAN 0 1 2 0 3 
244 SH3 domain-binding glutamic acid-rich-like protein OS=Homo 
sapiens GN=SH3BGRL PE=1 SV=1 
SH3L1_HUMAN 1 0 1 1 4 
245 T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 
PE=1 SV=4 
TCPB_HUMAN 0 0 0 2 1 
246 Collagen alpha-2(IV) chain OS=Homo sapiens GN=COL4A2 PE=1 
SV=4 
CO4A2_HUMAN 0 1 0 3 0 
247 Filamin-C OS=Homo sapiens GN=FLNC PE=1 SV=3 FLNC_HUMAN 0 1 2 0 2 
248 Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2 ANXA1_HUMAN 0 0 0 3 2 
249 Lysosomal protective protein OS=Homo sapiens GN=CTSA PE=1 
SV=2 
PPGB_HUMAN 4 0 1 1 0 
250 Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 PE=1 
SV=3 
TPM4_HUMAN 0 0 0 2 1 
251 Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 3 0 0 1 0 
252 Actin-related protein 3 OS=Homo sapiens GN=ACTR3 PE=1 SV=3 ARP3_HUMAN 0 0 0 2 5 
253 Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform OS=Homo sapiens GN=PPP2R1A PE=1 
SV=4 
2AAA_HUMAN 0 0 0 0 6 
254 Collagen alpha-1(XVIII) chain OS=Homo sapiens GN=COL18A1 
PE=1 SV=5 
COIA1_HUMAN 4 0 0 0 0 
255 Heterogeneous nuclear ribonucleoprotein D0 OS=Homo sapiens 
GN=HNRNPD PE=1 SV=1 
HNRPD_HUMAN 1 1 1 2 2 
256 Small ubiquitin-related modifier 2 OS=Homo sapiens 
GN=SUMO2 PE=1 SV=3 
SUMO2_HUMAN 1 1 1 1 2 
257 Hypoxanthine-guanine phosphoribosyltransferase OS=Homo 
sapiens GN=HPRT1 PE=1 SV=2 
HPRT_HUMAN 2 0 1 1 1 
258 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 APOE_HUMAN 0 1 0 2 1 
259 Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 NPM_HUMAN 0 1 0 2 1 
260 Cysteine-rich motor neuron 1 protein OS=Homo sapiens 
GN=CRIM1 PE=1 SV=1 
CRIM1_HUMAN 2 0 4 0 0 
261 Growth-regulated alpha protein OS=Homo sapiens GN=CXCL1 
PE=1 SV=1 
GROA_HUMAN 1 0 0 2 2 
262 Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 ANXA5_HUMAN 0 0 2 2 1 
263 6-phosphogluconate dehydrogenase, decarboxylating OS=Homo 
sapiens GN=PGD PE=1 SV=3 
6PGD_HUMAN 0 1 0 1 4 
264 Hepatocyte growth factor receptor OS=Homo sapiens GN=MET 
PE=1 SV=4 
MET_HUMAN 4 1 0 0 0 
265 Receptor-type tyrosine-protein phosphatase F OS=Homo sapiens 
GN=PTPRF PE=1 SV=2 
PTPRF_HUMAN 1 0 0 3 0 
266 Protein S100-A11 OS=Homo sapiens GN=S100A11 PE=1 SV=2 S10AB_HUMAN 2 0 0 1 1 
267 Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A PE=1 
SV=1 
RAB7A_HUMAN 1 0 0 1 3 
268 Histidine triad nucleotide-binding protein 1 OS=Homo sapiens 
GN=HINT1 PE=1 SV=2 
HINT1_HUMAN 0 0 0 2 3 
269 Follistatin OS=Homo sapiens GN=FST PE=1 SV=2 FST_HUMAN 0 0 0 5 0 
270 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 OS=Homo 
sapiens GN=PLOD3 PE=1 SV=1 
PLOD3_HUMAN 0 1 2 1 0 
271 Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC PE=1 
SV=2 
TFR1_HUMAN 2 0 1 1 1 
272 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 1433T_HUMAN 1 0 1 2 1 
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273 Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1 CALR_HUMAN 0 1 0 2 2 
274 Endothelial protein C receptor OS=Homo sapiens GN=PROCR 
PE=1 SV=1 
EPCR_HUMAN 3 1 0 1 0 
275 Legumain OS=Homo sapiens GN=LGMN PE=1 SV=1 LGMN_HUMAN 1 0 0 2 2 
276 Desmocollin-3 OS=Homo sapiens GN=DSC3 PE=1 SV=3 DSC3_HUMAN 3 0 1 1 0 
277 Heat shock protein 105 kDa OS=Homo sapiens GN=HSPH1 PE=1 
SV=1 
HS105_HUMAN 0 0 0 3 2 
278 Histone-binding protein RBBP4 OS=Homo sapiens GN=RBBP4 
PE=1 SV=3 
RBBP4_HUMAN 0 0 0 1 2 
279 Adenylyl cyclase-associated protein 1 OS=Homo sapiens 
GN=CAP1 PE=1 SV=5 
CAP1_HUMAN 0 0 0 1 4 
280 Fibroblast growth factor-binding protein 1 OS=Homo sapiens 
GN=FGFBP1 PE=1 SV=1 
FGFP1_HUMAN 3 0 0 1 0 
281 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 
SV=2 
HSPB1_HUMAN 2 0 0 3 0 
282 Basement membrane-specific heparan sulfate proteoglycan core 
protein OS=Homo sapiens GN=HSPG2 PE=1 SV=4 
PGBM_HUMAN 4 0 0 0 0 
283 Collagen alpha-1(IV) chain OS=Homo sapiens GN=COL4A1 PE=1 
SV=3 
CO4A1_HUMAN 0 1 1 2 1 
284 Inositol monophosphatase 1 OS=Homo sapiens GN=IMPA1 PE=1 
SV=1 
IMPA1_HUMAN 1 0 2 1 1 
285 Macrophage-capping protein OS=Homo sapiens GN=CAPG PE=1 
SV=2 
CAPG_HUMAN 1 0 0 1 2 
286 Insulin-like growth factor II OS=Homo sapiens GN=IGF2 PE=1 
SV=1 
IGF2_HUMAN 1 0 0 1 2 
287 Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 SV=1 TBB4B_HUMAN 1 0 0 3 2 
288 Ras-related protein Rab-1A OS=Homo sapiens GN=RAB1A PE=1 
SV=3 
RAB1A_HUMAN 1 0 1 0 3 
289 40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 RS5_HUMAN 1 0 0 1 2 
290 Proprotein convertase subtilisin/kexin type 9 OS=Homo sapiens 
GN=PCSK9 PE=1 SV=3 
PCSK9_HUMAN 0 0 0 1 3 
291 Dipeptidyl peptidase 1 OS=Homo sapiens GN=CTSC PE=1 SV=2 CATC_HUMAN 2 1 0 0 0 
292 Proteasome subunit alpha type-3 OS=Homo sapiens GN=PSMA3 
PE=1 SV=2 
PSA3_HUMAN 0 0 0 2 2 
293 Actin-related protein 2/3 complex subunit 3 OS=Homo sapiens 
GN=ARPC3 PE=1 SV=3 
ARPC3_HUMAN 0 0 0 1 2 
294 Serpin H1 OS=Homo sapiens GN=SERPINH1 PE=1 SV=2 SERPH_HUMAN 0 0 0 3 1 
295 Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 
SV=3 
CBR1_HUMAN 0 0 1 2 1 
296 F-actin-capping protein subunit alpha-1 OS=Homo sapiens 
GN=CAPZA1 PE=1 SV=3 
CAZA1_HUMAN 0 0 1 2 1 
297 DNA-(apurinic or apyrimidinic site) lyase OS=Homo sapiens 
GN=APEX1 PE=1 SV=2 
APEX1_HUMAN 0 0 1 2 2 
298 Multiple inositol polyphosphate phosphatase 1 OS=Homo 
sapiens GN=MINPP1 PE=1 SV=1 
MINP1_HUMAN 2 1 1 0 0 
299 Guanine nucleotide-binding protein subunit beta-2-like 1 
OS=Homo sapiens GN=GNB2L1 PE=1 SV=3 
GBLP_HUMAN 1 0 1 2 0 
300 Endoplasmic reticulum aminopeptidase 1 OS=Homo sapiens 
GN=ERAP1 PE=1 SV=3 
ERAP1_HUMAN 0 0 0 2 0 
301 40S ribosomal protein S28 OS=Homo sapiens GN=RPS28 PE=1 
SV=1 
RS28_HUMAN 1 0 0 1 2 
302 Glypican-1 OS=Homo sapiens GN=GPC1 PE=1 SV=2 GPC1_HUMAN 3 0 0 1 0 
303 Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 
PE=1 SV=3 
K2C1B_HUMAN 0 1 2 0 0 
304 Vascular endothelial growth factor C OS=Homo sapiens 
GN=VEGFC PE=1 SV=1 
VEGFC_HUMAN 3 0 0 0 0 
305 Renin receptor OS=Homo sapiens GN=ATP6AP2 PE=1 SV=2 RENR_HUMAN 3 0 0 2 0 
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306 Tumor necrosis factor receptor superfamily member 6B 
OS=Homo sapiens GN=TNFRSF6B PE=1 SV=1 
TNF6B_HUMAN 2 0 0 3 0 
307 Glutamate dehydrogenase 1, mitochondrial OS=Homo sapiens 
GN=GLUD1 PE=1 SV=2 
DHE3_HUMAN 0 0 3 0 0 
308 Endoplasmic reticulum resident protein 29 OS=Homo sapiens 
GN=ERP29 PE=1 SV=4 
ERP29_HUMAN 0 0 1 2 0 
309 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 RS3_HUMAN 4 0 0 0 0 
310 Integrin beta-1 OS=Homo sapiens GN=ITGB1 PE=1 SV=2 ITB1_HUMAN 0 1 1 0 2 
311 Beta-hexosaminidase subunit beta OS=Homo sapiens GN=HEXB 
PE=1 SV=3 
HEXB_HUMAN 2 1 0 0 2 
312 Destrin OS=Homo sapiens GN=DSTN PE=1 SV=3 DEST_HUMAN 1 0 0 1 2 
313 Thioredoxin domain-containing protein 5 OS=Homo sapiens 
GN=TXNDC5 PE=1 SV=2 
TXND5_HUMAN 0 0 1 2 0 
314 Protein disulfide-isomerase A4 OS=Homo sapiens GN=PDIA4 
PE=1 SV=2 
PDIA4_HUMAN 0 1 0 2 0 
315 C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens 
GN=MTHFD1 PE=1 SV=3 
C1TC_HUMAN 0 0 0 1 2 
316 Glyoxalase domain-containing protein 4 OS=Homo sapiens 
GN=GLOD4 PE=1 SV=1 
GLOD4_HUMAN 0 1 3 0 0 
317 ATP-citrate synthase OS=Homo sapiens GN=ACLY PE=1 SV=3 ACLY_HUMAN 0 0 0 0 2 
318 D-dopachrome decarboxylase OS=Homo sapiens GN=DDT PE=1 
SV=3 
DOPD_HUMAN 1 0 0 0 3 
319 Transgelin OS=Homo sapiens GN=TAGLN PE=1 SV=4 TAGL_HUMAN 1 0 0 0 2 
320 PDZ and LIM domain protein 1 OS=Homo sapiens GN=PDLIM1 
PE=1 SV=4 
PDLI1_HUMAN 1 0 0 0 2 
321 14-3-3 protein sigma OS=Homo sapiens GN=SFN PE=1 SV=1 1433S_HUMAN 0 0 0 2 1 
322 Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 
PE=1 SV=4 
PRDX5_HUMAN 0 0 0 0 3 
323 40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 
SV=3 
RS18_HUMAN 0 0 0 0 3 
324 Lysine--tRNA ligase OS=Homo sapiens GN=KARS PE=1 SV=3 SYK_HUMAN 0 0 0 0 2 
325 Protein SET OS=Homo sapiens GN=SET PE=1 SV=3 SET_HUMAN 0 0 0 3 0 
326 Phosphoserine aminotransferase OS=Homo sapiens GN=PSAT1 
PE=1 SV=2 
SERC_HUMAN 0 2 1 0 1 
327 T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 
PE=1 SV=2 
TCPH_HUMAN 0 1 0 2 1 
328 Protein jagged-1 OS=Homo sapiens GN=JAG1 PE=1 SV=3 JAG1_HUMAN 1 0 0 1 2 
329 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 
OS=Homo sapiens GN=B3GNT1 PE=1 SV=1 
B3GN1_HUMAN 0 0 0 1 2 
330 Palmitoyl-protein thioesterase 1 OS=Homo sapiens GN=PPT1 
PE=1 SV=1 
PPT1_HUMAN 2 0 0 1 0 
331 Chloride intracellular channel protein 4 OS=Homo sapiens 
GN=CLIC4 PE=1 SV=4 
CLIC4_HUMAN 0 0 0 2 3 
332 Lysosome-associated membrane glycoprotein 1 OS=Homo 
sapiens GN=LAMP1 PE=1 SV=3 
LAMP1_HUMAN 0 2 2 0 0 
333 60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 
SV=2 
RL11_HUMAN 0 0 0 1 2 
334 UMP-CMP kinase OS=Homo sapiens GN=CMPK1 PE=1 SV=3 KCY_HUMAN 0 0 0 1 2 
335 Ubiquitin-conjugating enzyme E2 D3 OS=Homo sapiens 
GN=UBE2D3 PE=1 SV=1 
UB2D3_HUMAN 0 0 0 1 2 
336 Importin-7 OS=Homo sapiens GN=IPO7 PE=1 SV=1 IPO7_HUMAN 0 0 0 0 2 
337 Beta-galactosidase OS=Homo sapiens GN=GLB1 PE=1 SV=2 BGAL_HUMAN 2 0 0 0 0 
338 G-protein coupled receptor 126 OS=Homo sapiens GN=GPR126 
PE=1 SV=3 
GP126_HUMAN 2 0 0 0 0 
339 Calsyntenin-3 OS=Homo sapiens GN=CLSTN3 PE=1 SV=1 CSTN3_HUMAN 3 0 0 0 0 
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340 Cochlin OS=Homo sapiens GN=COCH PE=1 SV=1 COCH_HUMAN 0 0 0 1 2 
341 Ras-related C3 botulinum toxin substrate 1 OS=Homo sapiens 
GN=RAC1 PE=1 SV=1 
RAC1_HUMAN 1 0 0 0 2 
342 RNA-binding motif protein, X chromosome OS=Homo sapiens 
GN=RBMX PE=1 SV=3 
RBMX_HUMAN 2 0 0 2 0 
343 Serpin B5 OS=Homo sapiens GN=SERPINB5 PE=1 SV=2 SPB5_HUMAN 0 0 0 2 1 
344 Signal recognition particle 9 kDa protein OS=Homo sapiens 
GN=SRP9 PE=1 SV=2 
SRP09_HUMAN 1 0 0 0 2 
345 Low molecular weight phosphotyrosine protein phosphatase 
OS=Homo sapiens GN=ACP1 PE=1 SV=3 
PPAC_HUMAN 0 0 0 1 2 
346 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 RS8_HUMAN 2 0 0 1 0 
347 CD109 antigen OS=Homo sapiens GN=CD109 PE=1 SV=2 CD109_HUMAN 0 0 0 2 1 
348 40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 
SV=3 
RS11_HUMAN 0 0 0 0 4 
349 40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 
SV=2 
RS19_HUMAN 0 0 0 0 3 
350 ATP-dependent RNA helicase DDX39A OS=Homo sapiens 
GN=DDX39A PE=1 SV=2 
DX39A_HUMAN 0 0 0 0 2 
351 Proliferation-associated protein 2G4 OS=Homo sapiens 
GN=PA2G4 PE=1 SV=3 
PA2G4_HUMAN 0 0 0 2 0 
352 Bifunctional purine biosynthesis protein PURH OS=Homo sapiens 
GN=ATIC PE=1 SV=3 
PUR9_HUMAN 0 0 0 0 2 
353 NEDD8 OS=Homo sapiens GN=NEDD8 PE=1 SV=1 NEDD8_HUMAN 0 0 0 0 2 
354 ATP-binding cassette sub-family E member 1 OS=Homo sapiens 
GN=ABCE1 PE=1 SV=1 
ABCE1_HUMAN 0 0 0 0 2 
355 Alpha-galactosidase A OS=Homo sapiens GN=GLA PE=1 SV=1 AGAL_HUMAN 1 0 0 3 0 
356 Purine nucleoside phosphorylase OS=Homo sapiens GN=PNP 
PE=1 SV=2 
PNPH_HUMAN 1 0 0 2 0 
357 Ras-related protein R-Ras2 OS=Homo sapiens GN=RRAS2 PE=1 
SV=1 
RRAS2_HUMAN 1 0 0 0 2 
358 Alcohol dehydrogenase [NADP(+)] OS=Homo sapiens 
GN=AKR1A1 PE=1 SV=3 
AK1A1_HUMAN 0 0 0 2 1 
359 Inorganic pyrophosphatase OS=Homo sapiens GN=PPA1 PE=1 
SV=2 
IPYR_HUMAN 0 0 0 2 0 
360 Cysteine-rich protein 2 OS=Homo sapiens GN=CRIP2 PE=1 SV=1 CRIP2_HUMAN 0 0 0 0 2 
361 Glycogen phosphorylase, liver form OS=Homo sapiens GN=PYGL 
PE=1 SV=4 
PYGL_HUMAN 0 0 0 0 3 
362 Chromobox protein homolog 3 OS=Homo sapiens GN=CBX3 
PE=1 SV=4 
CBX3_HUMAN 0 0 0 2 0 
363 MUC5A_HUMAN-R MUC5A_HUMAN-R 0 0 0 0 2 
364 Pterin-4-alpha-carbinolamine dehydratase OS=Homo sapiens 
GN=PCBD1 PE=1 SV=2 
PHS_HUMAN 0 0 0 0 2 
365 60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 
SV=2 
RL22_HUMAN 0 0 0 0 2 
366 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 
SV=1 
RS20_HUMAN 0 0 0 0 2 
367 Acylamino-acid-releasing enzyme OS=Homo sapiens GN=APEH 
PE=1 SV=4 
ACPH_HUMAN 0 0 0 2 0 
368 CD70 antigen OS=Homo sapiens GN=CD70 PE=1 SV=2 CD70_HUMAN 0 0 0 2 0 
369 Protein canopy homolog 2 OS=Homo sapiens GN=CNPY2 PE=1 
SV=1 
CNPY2_HUMAN 0 0 0 2 0 
370 Calcyclin-binding protein OS=Homo sapiens GN=CACYBP PE=1 
SV=2 
CYBP_HUMAN 0 0 0 2 0 
371 Follistatin-related protein 3 OS=Homo sapiens GN=FSTL3 PE=1 
SV=1 
FSTL3_HUMAN 0 0 0 2 0 
372 Platelet-activating factor acetylhydrolase IB subunit gamma 
OS=Homo sapiens GN=PAFAH1B3 PE=1 SV=1 
PA1B3_HUMAN 0 0 0 2 0 
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373 Staphylococcal nuclease domain-containing protein 1 OS=Homo 
sapiens GN=SND1 PE=1 SV=1 
SND1_HUMAN 0 0 0 2 0 
374 T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 
PE=1 SV=1 
TCPA_HUMAN 0 0 0 2 0 
375 T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 
PE=1 SV=4 
TCPQ_HUMAN 0 0 0 2 0 
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Table 10-2 List of identified proteins in supernatants of primary monocytes 
Numbers on the right indicate the quantity of different identified peptides in each sample. arch = supernatants 
of 10 nM, 24 hours archazolid treated monocytes; co = supernatants 24 hours control treated monocytes; arch 
LPS = supernatants of 10 nM, 24 hours archazolid + LPS treated monocytes ; co LPS = supernatants 24 hours 
control + LPS treated monocytes 
# Identified Proteins (154) Accession Number arch co arch 
LPS 
co 
LPS 
1 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 
PE=1 SV=6 
K2C1_HUMAN 148 169 68 120 
2 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 FLNA_HUMAN 21 8 67 26 
3 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 91 57 65 85 
4 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 TSP1_HUMAN 96 77 59 75 
5 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 ACTB_HUMAN (+1) 67 37 52 53 
6 Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 MOES_HUMAN 19 6 48 43 
7 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 VIME_HUMAN 30 5 42 13 
8 Plastin-2 OS=Homo sapiens GN=LCP1 PE=1 SV=6 PLSL_HUMAN 30 9 40 38 
9 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 
PE=1 SV=6 
K1C10_HUMAN 119 134 39 112 
10 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 
K22E_HUMAN 85 88 38 57 
11 Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 ACTN4_HUMAN 19 21 33 13 
12 Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 VINC_HUMAN 17 1 32 17 
13 Fructose-bisphosphate aldolase A OS=Homo sapiens 
GN=ALDOA PE=1 SV=2 
ALDOA_HUMAN 14 13 31 18 
14 Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 MYH9_HUMAN 12  30 12 
15 Myeloperoxidase OS=Homo sapiens GN=MPO PE=1 SV=1 PERM_HUMAN 31 11 29 23 
16 Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 TKT_HUMAN 10 13 27 17 
17 Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 ACTN1_HUMAN 18 30 26 13 
18 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 
PE=1 SV=3 
K1C9_HUMAN 63 81 24 55 
19 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 PROF1_HUMAN 5 3 23 3 
20 L-lactate dehydrogenase B chain OS=Homo sapiens 
GN=LDHB PE=1 SV=2 
LDHB_HUMAN 21 5 22 18 
21 Integrin beta-2 OS=Homo sapiens GN=ITGB2 PE=1 SV=2 ITB2_HUMAN 22 25 21 16 
22 Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 TLN1_HUMAN 12  21 11 
23 Leukocyte elastase inhibitor OS=Homo sapiens 
GN=SERPINB1 PE=1 SV=1 
ILEU_HUMAN 10 2 20 22 
24 Plectin OS=Homo sapiens GN=PLEC PE=1 SV=3 PLEC_HUMAN 5 1 20 3 
25 Plasminogen activator inhibitor 2 OS=Homo sapiens 
GN=SERPINB2 PE=1 SV=2 
PAI2_HUMAN 18 14 19 26 
26 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 
PE=1 SV=3 
TPIS_HUMAN 21 10 19 18 
27 Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 ANXA2_HUMAN 10 4 18 7 
28 L-lactate dehydrogenase A chain OS=Homo sapiens 
GN=LDHA PE=1 SV=2 
LDHA_HUMAN 13  18 14 
29 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 ENOA_HUMAN 30 11 17 30 
30 Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2 ANXA1_HUMAN 4 4 16 6 
31 Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens 
GN=PPIA PE=1 SV=2 
PPIA_HUMAN 9 2 15 2 
32 Transitional endoplasmic reticulum ATPase OS=Homo 
sapiens GN=VCP PE=1 SV=4 
TERA_HUMAN 3 2 15 4 
33 Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 
SV=1 
FETUA_HUMAN 21 11 15 21 
34 Heat shock 70 kDa protein 1A/1B OS=Homo sapiens 
GN=HSPA1A PE=1 SV=5 
HSP71_HUMAN 3  15 12 
35 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 LYSC_HUMAN 12 8 14 7 
36 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 
1433Z_HUMAN 14 6 13 17 
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37 Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 GELS_HUMAN 6 7 13 7 
38 Heat shock cognate 71 kDa protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 
HSP7C_HUMAN 6  13 12 
39 Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 ANXA5_HUMAN 5 3 12 7 
40 Ras GTPase-activating-like protein IQGAP1 OS=Homo 
sapiens GN=IQGAP1 PE=1 SV=1 
IQGA1_HUMAN 1 1 12 5 
41 Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
GSTP1_HUMAN 7  12 5 
42 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 H4_HUMAN 8 22 11 8 
43 Histone H2B type 1-D OS=Homo sapiens GN=HIST1H2BD 
PE=1 SV=2 
H2B1D_HUMAN 13 7 10 5 
44 Lamin-B1 OS=Homo sapiens GN=LMNB1 PE=1 SV=2 LMNB1_HUMAN 4  10 4 
45 Interleukin-6 OS=Homo sapiens GN=IL6 PE=1 SV=1 IL6_HUMAN 4 5 10 4 
46 Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI 
PE=1 SV=4 
G6PI_HUMAN 4  10 11 
47 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo 
sapiens GN=GAPDH PE=1 SV=3 
G3P_HUMAN 12 4 10 7 
48 Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 TALDO_HUMAN 11 3 9 11 
49 Macrophage-capping protein OS=Homo sapiens GN=CAPG 
PE=1 SV=2 
CAPG_HUMAN 6  9 6 
50 Platelet glycoprotein Ib alpha chain OS=Homo sapiens 
GN=GP1BA PE=1 SV=1 
GP1BA_HUMAN 15 10 9 5 
51 Integrin alpha-M OS=Homo sapiens GN=ITGAM PE=1 SV=2 ITAM_HUMAN 17 4 9 10 
52 Actin-related protein 2/3 complex subunit 4 OS=Homo 
sapiens GN=ARPC4 PE=1 SV=3 
ARPC4_HUMAN 2  9 1 
53 Neutrophil elastase OS=Homo sapiens GN=ELANE PE=1 SV=1 ELNE_HUMAN 8  9 5 
54 Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 S10A9_HUMAN 4  8 2 
55 Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 
PE=1 SV=3 
PGK1_HUMAN 21 13 8 30 
56 Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3 TAGL2_HUMAN 5 1 8 4 
57 Serpin B6 OS=Homo sapiens GN=SERPINB6 PE=1 SV=3 SPB6_HUMAN   8 2 
58 Monocyte differentiation antigen CD14 OS=Homo sapiens 
GN=CD14 PE=1 SV=2 
CD14_HUMAN 10 3 8 8 
59 Malate dehydrogenase, cytoplasmic OS=Homo sapiens 
GN=MDH1 PE=1 SV=4 
MDHC_HUMAN 8 2 8 6 
60 Histone H2A type 1-D OS=Homo sapiens GN=HIST1H2AD 
PE=1 SV=2 
H2A1D_HUMAN (+4) 1 2 8 7 
61 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB 
PE=1 SV=3 
1433B_HUMAN 11 2 8 12 
62 Hexokinase-3 OS=Homo sapiens GN=HK3 PE=1 SV=2 HXK3_HUMAN 5 1 7  
63 Integrin alpha-IIb OS=Homo sapiens GN=ITGA2B PE=1 SV=3 ITA2B_HUMAN 6 1 7 5 
64 Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 PARK7_HUMAN 2 1 7 1 
65 Receptor-type tyrosine-protein phosphatase C OS=Homo 
sapiens GN=PTPRC PE=1 SV=2 
PTPRC_HUMAN 4  7 1 
66 Phosphatidylethanolamine-binding protein 1 OS=Homo 
sapiens GN=PEBP1 PE=1 SV=3 
PEBP1_HUMAN 1 1 7 1 
67 Fructose-bisphosphate aldolase C OS=Homo sapiens 
GN=ALDOC PE=1 SV=2 
ALDOC_HUMAN 2  7  
68 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 
SV=3 
A1AT_HUMAN 14 5 6 3 
69 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 
SV=3 
A2MG_HUMAN 18 7 6 8 
70 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 
SV=2 
1433G_HUMAN 11 2 6 10 
71 Rab GDP dissociation inhibitor beta OS=Homo sapiens 
GN=GDI2 PE=1 SV=2 
GDIB_HUMAN 4 1 6 7 
72 Malate dehydrogenase, mitochondrial OS=Homo sapiens 
GN=MDH2 PE=1 SV=3 
MDHM_HUMAN 4 2 6 4 
73 Tumor necrosis factor OS=Homo sapiens GN=TNF PE=1 SV=1 TNFA_HUMAN 4  6 2 
74 Fructose-1,6-bisphosphatase 1 OS=Homo sapiens GN=FBP1 
PE=1 SV=5 
F16P1_HUMAN  1 6 1 
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75 78 kDa glucose-regulated protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 
GRP78_HUMAN 5  6 6 
76 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A 
PE=1 SV=3 
K2C6A_HUMAN 21 35 6 19 
77 Heat shock 70 kDa protein 4 OS=Homo sapiens GN=HSPA4 
PE=1 SV=4 
HSP74_HUMAN 1 1 5 1 
78 Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 
SV=3 
COTL1_HUMAN 2 1 5 1 
79 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 TRFL_HUMAN 10 4 5 4 
80 6-phosphogluconate dehydrogenase, decarboxylating 
OS=Homo sapiens GN=PGD PE=1 SV=3 
6PGD_HUMAN 7 3 5 7 
81 Serpin B9 OS=Homo sapiens GN=SERPINB9 PE=1 SV=1 SPB9_HUMAN 9 1 5 2 
82 Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 
PE=1 SV=1 
URP2_HUMAN 2 1 5 1 
83 Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY 
PE=1 SV=4 
H2AY_HUMAN 2  5 1 
84 Nucleoside diphosphate kinase B OS=Homo sapiens 
GN=NME2 PE=1 SV=1 
NDKB_HUMAN 1  5 1 
85 Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 PRDX1_HUMAN 4  5 3 
86 Rho GDP-dissociation inhibitor 2 OS=Homo sapiens 
GN=ARHGDIB PE=1 SV=3 
GDIR2_HUMAN 4 1 5 5 
87 Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 
PE=1 SV=3 
TPM4_HUMAN 1  5 2 
88 Intercellular adhesion molecule 3 OS=Homo sapiens 
GN=ICAM3 PE=1 SV=2 
ICAM3_HUMAN 2 1 5 5 
89 Actin-related protein 2/3 complex subunit 1B OS=Homo 
sapiens GN=ARPC1B PE=1 SV=3 
ARC1B_HUMAN 6  5 3 
90 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 ENPL_HUMAN 1  5  
91 Heat shock protein HSP 90-alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 SV=5 
HS90A_HUMAN 2  4 4 
92 Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A 
PE=1 SV=1 
RAB7A_HUMAN   4  
93 Leukotriene A-4 hydrolase OS=Homo sapiens GN=LTA4H 
PE=1 SV=2 
LKHA4_HUMAN   4 5 
94 Cathepsin S OS=Homo sapiens GN=CTSS PE=1 SV=3 CATS_HUMAN 13  4  
95 Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 
PE=1 SV=2 
PGAM1_HUMAN 4 1 4 6 
96 Alcohol dehydrogenase [NADP(+)] OS=Homo sapiens 
GN=AKR1A1 PE=1 SV=3 
AK1A1_HUMAN 2 1 4 4 
97 Histone H3.1t OS=Homo sapiens GN=HIST3H3 PE=1 SV=3 H31T_HUMAN (+3) 5 2 4 1 
98 Adenylyl cyclase-associated protein 1 OS=Homo sapiens 
GN=CAP1 PE=1 SV=5 
CAP1_HUMAN 1  4 1 
99 Alpha-fetoprotein OS=Homo sapiens GN=AFP PE=1 SV=1 FETA_HUMAN 4 3 4 3 
100 Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 COF1_HUMAN 4 2 4 5 
101 Lysosome-associated membrane glycoprotein 1 OS=Homo 
sapiens GN=LAMP1 PE=1 SV=3 
LAMP1_HUMAN 3  4  
102 Actin-related protein 2/3 complex subunit 3 OS=Homo 
sapiens GN=ARPC3 PE=1 SV=3 
ARPC3_HUMAN 1  4 1 
103 Purine nucleoside phosphorylase OS=Homo sapiens GN=PNP 
PE=1 SV=2 
PNPH_HUMAN 2  4  
104 Glyoxalase domain-containing protein 4 OS=Homo sapiens 
GN=GLOD4 PE=1 SV=1 
GLOD4_HUMAN   4 1 
105 F-actin-capping protein subunit beta OS=Homo sapiens 
GN=CAPZB PE=1 SV=4 
CAPZB_HUMAN 3  4 4 
106 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 
SV=1 
1433E_HUMAN 3 1 4 3 
107 Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 
PE=1 SV=2 
PCBP1_HUMAN  1 3  
108 Acylamino-acid-releasing enzyme OS=Homo sapiens 
GN=APEH PE=1 SV=4 
ACPH_HUMAN  1 3 1 
109 N-acetyl-D-glucosamine kinase OS=Homo sapiens GN=NAGK 
PE=1 SV=4 
NAGK_HUMAN 2  3 1 
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110 Proteasome subunit beta type-9 OS=Homo sapiens 
GN=PSMB9 PE=1 SV=2 
PSB9_HUMAN 2 2 3 2 
111 Ferritin light chain OS=Homo sapiens GN=FTL PE=1 SV=2 FRIL_HUMAN 3 2 3 1 
112 F-actin-capping protein subunit alpha-1 OS=Homo sapiens 
GN=CAPZA1 PE=1 SV=3 
CAZA1_HUMAN 2  3 2 
113 Proteasome subunit alpha type-6 OS=Homo sapiens 
GN=PSMA6 PE=1 SV=1 
PSA6_HUMAN 2  3 3 
114 Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 1  3 2 
115 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo 
sapiens GN=ITIH2 PE=1 SV=2 
ITIH2_HUMAN 4  3  
116 Ubiquitin-conjugating enzyme E2 N OS=Homo sapiens 
GN=UBE2N PE=1 SV=1 
UBE2N_HUMAN (+1) 1  3 2 
117 Phospholipase B-like 1 OS=Homo sapiens GN=PLBD1 PE=1 
SV=2 
PLBL1_HUMAN 8  2  
118 Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 
PE=1 SV=1 
NPC2_HUMAN 3 2 2 1 
119 Ferritin heavy chain OS=Homo sapiens GN=FTH1 PE=1 SV=2 FRIH_HUMAN 6 1 2  
120 ATRIP_HUMAN-R ATRIP_HUMAN-R   2  
121 Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4 COR1A_HUMAN 6 2 2 9 
122 Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 
SV=3 
FIBG_HUMAN 10 5 2 9 
123 Tryptophan--tRNA ligase, cytoplasmic OS=Homo sapiens 
GN=WARS PE=1 SV=2 
SYWC_HUMAN 3  2 6 
124 Pyruvate kinase isozymes M1/M2 OS=Homo sapiens 
GN=PKM PE=1 SV=4 
KPYM_HUMAN 4 2 2 1 
125 Glutathione reductase, mitochondrial OS=Homo sapiens 
GN=GSR PE=1 SV=2 
GSHR_HUMAN 1 2 2 3 
126 Cathepsin Z OS=Homo sapiens GN=CTSZ PE=1 SV=1 CATZ_HUMAN 4  2 2 
127 Actin-related protein 2 OS=Homo sapiens GN=ACTR2 PE=1 
SV=1 
ARP2_HUMAN 1  2 4 
128 Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 EF2_HUMAN 4 1 2  
129 Isocitrate dehydrogenase [NADP] cytoplasmic OS=Homo 
sapiens GN=IDH1 PE=1 SV=2 
IDHC_HUMAN 4  2 1 
130 Ras-related C3 botulinum toxin substrate 1 OS=Homo 
sapiens GN=RAC1 PE=1 SV=1 
RAC1_HUMAN (+2) 4 1 2  
131 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 
SV=2 
FIBA_HUMAN 6 2 1 2 
132 MUC5A_HUMAN-R MUC5A_HUMAN-R 1 2 1 1 
133 Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 
PE=1 SV=4 
PDIA3_HUMAN 8 1 1 1 
134 Guanine nucleotide-binding protein G(i) subunit alpha-2 
OS=Homo sapiens GN=GNAI2 PE=1 SV=3 
GNAI2_HUMAN 2  1 3 
135 Aminopeptidase N OS=Homo sapiens GN=ANPEP PE=1 SV=4 AMPN_HUMAN 4  1  
136 Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 
PE=1 SV=2 
AACT_HUMAN 2  1  
137 N-acetylglucosamine-6-sulfatase OS=Homo sapiens GN=GNS 
PE=1 SV=3 
GNS_HUMAN 5  1  
138 Chloride intracellular channel protein 1 OS=Homo sapiens 
GN=CLIC1 PE=1 SV=4 
CLIC1_HUMAN 3  1 1 
139 Thymidine phosphorylase OS=Homo sapiens GN=TYMP PE=1 
SV=2 
TYPH_HUMAN 1 2 1 3 
140 Proteasome subunit alpha type-7 OS=Homo sapiens 
GN=PSMA7 PE=1 SV=1 
PSA7_HUMAN 2  1 2 
141 EMILIN-1 OS=Homo sapiens GN=EMILIN1 PE=1 SV=2 EMIL1_HUMAN 2 1 1  
142 Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2 ITB3_HUMAN 1 4 1  
143 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 CATA_HUMAN 1  1 2 
144 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 
PE=1 SV=4 
K1C14_HUMAN 26 37  26 
145 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 
PE=1 SV=3 
K2C5_HUMAN 11 26  12 
146 Matrix metalloproteinase-9 OS=Homo sapiens GN=MMP9 MMP9_HUMAN 2 7   
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PE=1 SV=3 
147 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
IGHG1_HUMAN 3 4  1 
148 Erythrocyte band 7 integral membrane protein OS=Homo 
sapiens GN=STOM PE=1 SV=3 
STOM_HUMAN 1 2  4 
149 Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 FIBB_HUMAN 1   3 
150 Beta-hexosaminidase subunit beta OS=Homo sapiens 
GN=HEXB PE=1 SV=3 
HEXB_HUMAN 4    
151 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 
PE=1 SV=4 
K1C16_HUMAN  31   
152 Lysosomal alpha-glucosidase OS=Homo sapiens GN=GAA 
PE=1 SV=4 
LYAG_HUMAN 4    
153 Adenosine deaminase CECR1 OS=Homo sapiens GN=CECR1 
PE=1 SV=2 
CECR1_HUMAN 2   1 
154 Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3 CATB_HUMAN 3    
 
